It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2021.12.03.21267251;](https://doi.org/10.1101/2021.12.03.21267251) this version posted December 5, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted

1 **Bacille Calmette-Guérin vaccine reprograms human neonatal lipid**

2 **metabolism** *in vitro* **and** *in vivo*

- 3
- 4 Joann Diray-Arce^{1,2,16,*}, Asimenia Angelidou^{1,2,3}, Kristoffer Jarlov Jensen^{4,5,6}, Maria Giulia
- 5 Conti^{1,7}, Rachel S. Kelly⁸, Matthew A. Pettengill^{1,9}, Mark Liu¹, Simon D. van Haren^{1,2}, Scott
- 6 McCulloch¹⁰, Greg Michelloti¹⁰, the EPIC Consortium[#], Tobias Kollmann¹¹, Beate Kampmann¹²,
- 7 Hanno Steen^{1,2,13}, Al Ozonoff^{1,2}, Jessica Lasky- Su⁸, Christine Stabell Benn^{3,5,14}, Ofer Levy^{1,2,15,*}
- 8
- ¹ 9 *Precision Vaccines Program*, Division of Infectious Diseases, Boston Children's Hospital,
- 10 Boston, Massachusetts, 02115, USA;
- ² Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, 02115, USA;
- ³ Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts,
- 13 02215, USA;
- ⁴ Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, University of
- 15 Southern Denmark, 2300, Copenhagen, Denmark;
- ⁵ 16 ⁵ Bandim Health Project, IN-DEPTH Network, 1004, Bissau, Guinea-Bissau;
- ⁶ Experimental and Translational Immunology, Department of Health Technology, Technical
- 18 University of Denmark, DK-2800 Kgs Lyngby, Denmark;
- ⁷ Department of Maternal and Child Health, Sapienza University of Rome, 00185, Rome, Italy
- 20 ⁸ Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical
- 21 School, Boston, Massachusetts, 02115, USA;
- ⁹ Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University,
- 23 Philadelphia, Pennsylvania, 19107, USA;
- 10^{10} Metabolon Inc. Morrisville, North Carolina, 27560, USA;
- ¹¹ Telethon Kids Institute, University of Western Australia, Perth, Western Australia, 6009,
- 26 Australia;
- ¹² The Vaccine Centre, Faculty of Infectious and Tropical Diseases, London School of Hygiene 28 and Tropical Medicine, London, WC1E 7HT, United Kingdom;
- ¹³ Department of Pathology, Boston Children's Hospital, Boston, Massachusetts, 02115, USA;
- 14 ¹⁴ OPEN, Institute of Clinical Research, University of Southern Denmark, 5000, Odense C,
- 31 Denmark;
- 15 32 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, 02142, USA;
- 33 ¹⁶ Lead contact
- 34 #The Expanded Program on Immunization (EPIC) Consortium
- 35
- 36 *Correspondence: joann.arce@childrens.harvard.edu, ofer.levy@childrens.harvard.edu
- 37
- 38 **Highlights**
- 39 Neonatal BCG immunization generates distinct metabolic shifts *in vivo* and *in vitro* 40 across multiple independent cohorts*.*
- 41 BCG induces prominent changes in concentrations of plasma lysophospholipids (LPLs)
- 42 BCG induced changes in plasma lysophosphatidylcholines (LPCs) correlate with BCG 43 effects on TLR agonist- and mycobacterial antigen-induced cytokine responses.
- 44 Characterization of vaccine-induced changes in metabolism may define predictive 45 signatures of vaccine responses and inform early life vaccine development.
- 46

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2021.12.03.21267251;](https://doi.org/10.1101/2021.12.03.21267251) this version posted December 5, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted

- 47 Keywords: BCG vaccines, early life vaccinology, lipidomics, lysophospholipids, metabolomics, newborn immunity, systems vaccinology, vaccines
- newborn immunity, systems vaccinology, vaccines

49

50 **Summary**

51 Vaccines have generally been developed with limited insight into their molecular impact. While 52 systems vaccinology, including metabolomics, enables new characterization of vaccine 53 mechanisms of action, these tools have yet to be applied to infants at high risk of infection and 54 receive the most vaccines. Bacille Calmette-Guérin (BCG) protects infants against disseminated 55 tuberculosis (TB) and TB-unrelated infections via incompletely understood mechanisms. We 56 employed mass spectrometry-based metabolomics of blood plasma to profile BCG-induced 57 infant responses in Guinea Bissau *in vivo* and the U.S. *in vitro*. BCG selectively altered plasma 58 lipid pathways, including lysophospholipids*.* BCG-induced lysophosphatidylcholines (LPCs) 59 correlated with both TLR agonist- and purified protein derivative (PPD, mycobacterial antigen)- 60 induced blood cytokine production *in vitro*, raising the possibility that LPCs contribute to BCG 61 immunogenicity. Analysis of an independent newborn cohort from The Gambia demonstrated 62 shared vaccine-induced metabolites such as phospholipids and sphingolipids. BCG-induced 63 changes to the plasma lipidome and LPCs may contribute to its immunogenicity and inform the 64 discovery and development of early life vaccines.

65 **Introduction:**

66 Infectious diseases are the leading cause of early life mortality worldwide, with \sim 2.5 67 million newborns and infants dying from infections each year (World Health, 2020). 68 Approximately 45% of deaths in children under five years of age occurred during the neonatal 69 period, defined as the first 28 days of life (World Health, 2020). Immunization is a cost-effective 70 public health intervention that reduces the risk of morbidity and averts \sim 2 to 3 million deaths 71 every year. Protective responses to immunization in early life are different from those in older 72 individuals, in part due to the distinct immune system of newborns and young infants (Dowling 73 and Levy, 2014; Sanchez-Schmitz and Levy, 2011). Characterizing sex-, age- and antigen-74 specific responses is key to developing vaccines tailored for vulnerable populations such as the 75 very young (Whittaker et al., 2018).

76

77 Immunization at birth with live-attenuated *Mycobacterium bovis* vaccines, referred to as 78 Bacille Calmette-Guérin (BCG), is recommended in countries with endemic tuberculosis (TB) to 79 protect infants against miliary TB and tuberculous meningitis (Mangtani et al., 2014). Though 80 there are no definite correlates of protection, some studies have linked BCG efficacy against TB 81 to its ability to effectively induce Th1-polarized neonatal immune responses (Libraty et al., 2014; 82 Marchant et al., 1999). Remarkably, across multiple studies, the administration of BCG in early 83 life has been associated with a reduced incidence of unrelated ("off-target") infections. Such 84 beneficial pathogen-agnostic ("heterologous") effects of BCG are hypothesized to reduce 85 morbidity and mortality far beyond what is expected from prevention of the target disease- i.e., 86 TB (Higgins et al., 2016). For example, three consecutive randomized trials demonstrated that 87 early administration of BCG to low birth weight newborns in Guinea-Bissau significantly 88 reduced mortality by ~38% (17%-54%) (Biering-Sorensen et al., 2017). BCG pathogen-agnostic 89 effects are still under investigation and may not be evident in all settings (Haahr et al., 2016; 90 Kjaergaard et al., 2016); therefore, identifying high-risk populations may benefit most from BCG 91 vaccination is an active area of research. The rapid beneficial effects of BCG in early life suggest 92 that it may be mediated via innate immunity. The mechanisms mediating BCG protection are 93 under active investigation (Curtis et al., 2020; Moorlag et al., 2019; Zimmermann et al., 2019), 94 with recent evidence suggesting that induction of granulopoiesis may contribute to BCG-induced 95 protection against off-target bacterial infections in early life (Brook et al., 2020). 96

97 One potential mechanism for the heterologous effects of BCG is epigenetic 98 reprogramming of human innate immune cells, i.e., trained immunity, resulting in altered innate 99 immune responses upon rechallenge with heterologous stimuli in adults (Kleinnijenhuis et al., 100 2012). Systemic metabolic pathways have been implicated in the immune system regulation 101 (Boothby and Rickert, 2017). A potential role for metabolism in the protective effects of BCG 102 has been posited (Kelly and O'Neill, 2015). Training effects may be mediated by metabolites 103 functioning as cofactors for epigenetic enzymes to induce chromatin and DNA modifications; 104 upon rechallenge with a second stimulus that is unrelated to the first stimulus that induces 105 training, trained cells can mount a more rapid and effective immune response (Netea et al., 106 2016). Changes in glucose, glutamine, and cholesterol metabolism maintain trained immunity 107 through the provision of active intermediate metabolites (Fok et al., 2019). Vaccine-induced 108 metabolic changes that contribute to trained immunity have been studied in adults. Still, the 109 impact of the BCG vaccine on human neonatal metabolism has yet to be characterized 110 (Kollmann, 2013). Given newborns' unique developmental physiology and nutritional/metabolic

111 needs compared to adults, vaccine-induced metabolic changes may be age-dependent (Angelidou 112 et al., 2021; Conti et al., 2020).

113

114 The human metabolome is influenced by physiologic or pathologic states and 115 environmental factors, such as nutrition (Johnson et al., 2016; Playdon et al., 2017), and consists 116 of by-products from signaling cascades. Metabolomics, the study of small molecules associated 117 with physiologic conditions, has been used to identify active or dysregulated pathways (Guijas et 118 al., 2018) in health and disease. Metabolites can define disease phenotypes and are often readily 119 measured and applied to clinical settings (Johnson et al., 2016). Circulating metabolites can have 120 immunomodulatory effects, and, conversely, immune activation can shape the plasma 121 metabolome and predict future disease phenotypes (Diray-Arce et al., 2020; Pettengill et al., 122 2014). While several metabolites in neonatal monocytes and macrophages such as acetyl-123 coenzyme A and succinate play a role in the induction of epigenetic modulators, essential to 124 trained immunity, much remains to be learned regarding the distinct neonatal 125 immunometabolism (Arts et al., 2018; Conti et al., 2020; Kan et al., 2018; Reinke et al., 2013). 126 We have recently demonstrated that mass spectrometry-based metabolomics can be applied to 127 newborn plasma samples (Lee et al., 2019), and there is great interest in applying these powerful 128 technologies to characterize neonatal vaccine responses (Amenyogbe et al., 2015; Hagan et al., 129 2015; Petrick et al., 2019). However, to date, no published systems vaccinology studies have 130 assessed systemic metabolic responses of newborns to immunization. 131 132 In this study, we examined the effects of neonatal BCG vaccination on the global 133 metabolic profile in newborn blood plasma at four weeks of life. Subsequently, we investigated 134 how BCG vaccination impacts the plasma lipidome and both antigen-specific and innate 135 cytokine induction. We report that BCG vaccination induces metabolic shifts *in vivo* and *in vitro*,

136 particularly in lysolipid pathways, including lysophosphatidylcholines (LPCs) that correlate with

137 TLR agonist- and purified protein derivative (PPD, mycobacterial antigen)-induced whole blood

138 cytokine responses. Our observations provide fresh insights into BCG's potential mechanisms of action, identify new candidate pathways and biomarkers that may inform optimization of its

action, identify new candidate pathways and biomarkers that may inform optimization of its

140 beneficial effects, and suggest that vaccine-induced metabolites are relevant to vaccine

141 immunogenicity.

142 143

144 **Results:**

145 **BCG vaccination induced shifts in the infant plasma metabolome**

146

147 To elucidate the impact of early BCG vaccination, plasma samples from *in vivo* and *in* 148 *vitro* cohorts were subjected to comprehensive metabolomics analysis. Our primary *in vivo* 149 cohort consisted of low birthweight newborns from Guinea-Bissau who were enrolled in a 150 randomized clinical trial to receive BCG at birth (classified as early BCG) or at six weeks after 151 birth (delayed BCG) (Biering-Sorensen et al., 2017). In an immunological study nested within 152 the trial, capillary blood samples were collected four weeks after randomization (after BCG was 153 given in the early BCG group and before BCG was given in the delayed BCG group) to 154 investigate the effect of BCG on PPD antigen- and TLR-agonist-induced whole blood cytokine 155 responses *in vitro* (Figure 1A) (Jensen et al., 2015). Catch-up vaccination followed at six weeks 156 of life with Pentavalent vaccine (Penta) and oral polio vaccine (OPV) for the early BCG group 157 and BCG, Penta, and OPV for the delayed BCG group (Figure 2A).

158

159 After the primary analyses (Jensen et al., 2015), blood samples with the remaining 160 plasma of sufficient volume were shipped to the *Precision Vaccines Program* (Boston, MA, 161 USA) for subsequent assays. Study design, including the enrollment and randomization 162 procedures and sample processing of the immunological sub-study, is outlined in Figure S1A-163 S1C. Characteristics of newborn study participants whose plasma was subjected to metabolomic

- 164 profiling are described in Table S1.
- 165

166 Ultrahigh performance liquid chromatography-tandem mass spectroscopy (UPLC-167 MS/MS) (*Metabolon*; Morrisville, NC, USA) was employed to identify and measure metabolites 168 in the human newborn plasma (Evans et al., 2009). To ensure sufficient plasma volume for this 169 assay, we pooled plasma samples of 10 participants stratified by sex and treatment prior to mass 170 spectrometry analysis. Mass spectrometry peaks were identified based on their corresponding 171 retention time/index (RI), mass to charge ratio (m/z) , and chromatographic data compared with
172 *Metabolon's* library of purified standards or recurrent unknown entities. To reduce the *Metabolon*'s library of purified standards or recurrent unknown entities. To reduce the 173 dimensionality of the data and identify the discriminative overview of the metabolomes 174 classified by grouping, we conducted a supervised sparse Partial Least Square Discriminant 175 Analysis (sPLS-DA). We extracted two components, Component 1 (Comp 1) and Component 2 176 (Comp 2), which accounted for 15% and 11% of the variation, respectively (Figure 2B). The first 177 two components elucidated distinct clustering between delayed BCG and early BCG, suggesting 178 that early BCG immunization induced shifts in the plasma metabolome. The top 30 loadings 179 identified metabolites associated with early BCG (orange) and delayed BCG (blue), including 180 several glycerophospholipids (GPCs), increased in the early BCG group (Figure 2C). 181

182 Of the 674 metabolites detected, 623 passed quality control and assurance. We focused 183 on endogenous biochemicals in which 544 metabolites were included in the analysis (Figure 184 S2A-E). Among these metabolites, 55 biochemicals (10.11%) demonstrated significantly 185 differential abundance between the early vs. delayed BCG newborn groups (alpha=0.05) (Table 186 S2, Figure 2E). A majority of significant metabolites belonged to the lipid superclass.
187 Unsupervised hierarchical clustering of differentially abundant metabolites (DAMs) il 187 Unsupervised hierarchical clustering of differentially abundant metabolites (DAMs) illustrated 188 higher levels of lipid metabolites in the early BCG compared to the delayed BCG group. In

189 contrast, early vs. late BCG administration was associated with lower plasma amino acid 190 concentrations (Figure 2D).

191

192 **BCG induced prominent shifts in plasma lipid pathways**

193 Compared to the delayed BCG group, early BCG administration was associated with 194 distinct concentrations of a range of lipid pathways and metabolites. Of note, greater than half of 195 the metabolites whose levels changed significantly (p< 0.05) between the groups belonged to the 196 lipid superclass (Figure 3A), and 39% of DAMs were of the lysophospholipid (LPL) subclass 197 (Figure 3A). Early BCG administration was consistently associated with robust production of 198 selected sphingolipid, monoacylglycerol, steroid, and LPL metabolites (Table S2). In contrast, 199 palmitoylglycerols and pregnanediol disulfate (progestin steroids) were decreased in the early vs. 200 delayed BCG group (Figure 3B, Table S2).

201

202 We used pathway-based network reconstruction (implementation: *Metscape* plugin of 203 *Cytoscape*) to construct a compound network providing a comprehensive overview of metabolic 204 signatures to compare early vs. delayed BCG newborn groups (Figure 3C). As BCG 205 administration at birth was associated with high production of lipid metabolites, our network 206 demonstrated that glycerolipid pathways were interrelated and shared common nodes with other 207 metabolic pathways (e.g., bile acid biosynthesis, galactose glycerophospholipid, 208 glycosphingolipid, and linoleate metabolism). In addition, we utilized metabolite set enrichment 209 analysis (MSEA), which takes into account the quantitative measurement of each metabolite and 210 groups them into functionally related sets from a collection of predefined human metabolic 211 pathways (Jia et al., 2014). Results from MSEA were consistent with observations from network 212 reconstruction, suggesting a prominent role for lipids upon early BCG vaccination in newborns 213 (Figure 3C, Table S3). Early BCG administration was associated with increased production of 214 multiple metabolites of the glycosphingolipid and glycerophospholipids, including LPCs. In 215 contrast, glycerol, phosphoethanolamines, and cortisol were decreased in the early vs. delayed 216 BCG group. 217

218 To gain further insight into the effects of BCG on the infant plasma lipidome, we assayed 219 the same *in vivo* samples (i.e., those characterized using the untargeted metabolomics platform)
220 using Complex Lipid Panel LC-MS/MS-based lipidomics (Figure 4A). Across the 14 lipid using Complex Lipid Panel LC-MS/MS-based lipidomics (Figure 4A). Across the 14 lipid 221 classes identified by this assay, we identified a total of 963 lipids, with triacylglycerol (TAG) 222 being the most abundant lipid subclass, followed by phosphatidylethanolamines (PEs) and 223 phosphatidylcholine (Figure 4B). Separation of groups by the timing of BCG vaccination (early 224 vs. delayed) accounted for 52% variance at Comp 1 and 15% at Comp 2 (Figure 4C). A total of 225 30 lipids (3.1%) were significantly perturbed, comparing early vs. delayed BCG newborns 226 (Figure 4D). Four free fatty acid components (FFA 20:0, 22:2, 22:4, 24:0) demonstrated 227 increased concentration in the early BCG group. Early BCG administration was associated with 228 decreased concentrations of most LPC metabolites except LPC (22:2), which was significantly 229 increased. BCG immunization was associated with lower plasma concentrations of multiple lipid 230 sub-pathway families, including lysophosphatidylethanolamines (LPEs 18:2, 20:3, 20:4, 22:4), 231 monoacylglycerols (MAGs 12:0, 14:0, 16:0, 16:1, 18:1, 18:2, 18:3, 22:5, 22:6), phosphocholines
232 (PCs 14:0/16:1 and 16:0/22:2), PEs (18:0/22:2, 18:1/22:0, and 18:2/16:1) and TAGs (TAG44:0-232 (PCs 14:0/16:1 and 16:0/22:2), PEs (18:0/22:2, 18:1/22:0, and 18:2/16:1) and TAGs (TAG44:0- 233 FA18:0, TAG53:5-FA18:3, and TAG56:6/FA22:4) (Table S4).

234

235 **BCG induced metabolic signatures** *in vitro* **mirror those induced by early BCG vaccination** 236 *in vivo*

237

238 We hypothesized that BCG-induced metabolic signatures detected *in vivo* could be 239 modeled *in vitro*. To this end, we obtained human cord blood from a Boston newborn cohort 240 (full-term newborns delivered via cesarean section) and assessed responses utilizing a whole 241 blood assay (WBA) (Figure 1B) (Angelidou et al., 2020a). The WBA features multiple 242 advantages, including (a) utilization of small volumes of minimally perturbed primary 243 leukocytes, (b) the presence of autologous plasma, a rich source of age-specific 244 immunomodulatory components (e.g., maternal antibodies, adenosine, etc.) (Pettengill et al., 245 2014), and (c) the ability to model and analyze responses of each participant to multiple 246 conditions such as vehicle control and BCG-stimulation. WBA-derived supernatants (90% 247 plasma v/v) were subjected to high-throughput metabolomics and complex lipid panel lipidomics 248 (WBA; Figures S1B and 1B). Untargeted metabolomics detected 568 metabolites and analyzed 249 437 metabolites after quality control and assurance and filtering out the xenobiotics to focus on 250 endogenous metabolites (Figure S2F-J). BCG-only samples (i.e., no blood) at low and high 251 dilution were also assayed as additional controls to assess background and identify metabolites 252 produced by the BCG vaccine itself (Figure S3A). BCG-only controls demonstrated lower 253 measurable concentrations in most lipid families (Figure S3B). Also, they had a lower number of 254 detected lipids (Figure S3C) compared to cord blood stimulated with vehicle or with BCG. 255 Matched pairs or pairwise comparisons of samples from the same participant were used for 256 analysis.

257

258 Principal component analysis (PCA) of metabolites detected in plasma from the *in vitro* 259 stimulation assay illustrated that BCG treatment induced changes in the plasma metabolome 260 (Figure 5A). Hierarchical clustering demonstrated the grouping of metabolite levels by treatment 261 (Figure 5B). Metabolite set enrichment analysis (MSEA) using relative metabolite 262 concentrations from the Boston *in vitro* cohort identified the glucose-alanine cycle, lactose 263 degradation pathway, and sphingolipid metabolism as the top enriched pathways after BCG 264 stimulation (Figure 5C). Metabolites that significantly differed between BCG-stimulated vs. 265 control conditions *in vitro* included 25 upregulated metabolites and 77 down-regulated 266 metabolites (Figure 5D, Table S5). A comparison between the in vivo Guinea Bissau and the in 267 vitro Boston cohorts revealed 47 shared enriched metabolic pathways, representing a 58% 268 overlap (Figure 7A). The number of unique pathways identified in BCG-stimulated samples *in* 269 *vitro* (19 pathways: 23.5%) was slightly higher than that in the early BCG group *in vivo* (15 270 pathways: 18.5%) (Figure 7A). Our results suggest more acute metabolic changes detected *in* 271 *vitro* (18 hr post-BCG stimulation) than four weeks post *in vivo* BCG vaccination. 272

273 Lipidomic analysis of supernatants from whole blood stimulated with BCG *in vitro* 274 identified 963 lipids belonging to 15 families. Among those, only 75 lipids (7.6%) were 275 significantly perturbed, with most lipids decreased upon BCG stimulation (Figure 4E). BCG 276 stimulation induced a decrease of several plasma phospholipids metabolism intermediates, such 277 as choline phosphate, glycerophosphocholine (GPC), and phosphoethanolamine (PE) (Table S7). 278 Similar to total metabolic changes, more acute differences were noted for lipids stimulated *in* 279 *vitro* (18 hr stim) compared to *in vivo* (4 weeks post-vaccine), possibly reflecting differences in 280 the kinetics of BCG-induced lipid changes (Figure 4F). Multiple LPC components (LPC 16:0,

281 18:2, 20:4, 22:6) and other lipids were also decreased in BCG-stimulated samples *in vitro* 282 (Figure 4G).

283

284 Previous studies have assessed the role of fatty acids and the eicosanoid pathway in Mtb 285 infection and BCG vaccine efficacy (McFarland et al., 2008). Eicosanoids are a family of lipid 286 mediators involved in inflammation (Figure S3F). Prostaglandin $E_2(PGE_2)$ was significantly 287 increased upon BCG stimulation (Figure S3D), while we observed a significant reduction in 288 docosahexaenoic acid (DHA 22:6 (n-3)) (Figure S3E) in BCG-stimulated samples vs. control. 289 Linoleic acid (FFA 18:2) and arachidonic acid (FFA $(20:4)$), an immediate precursor of PGE₂ 290 (Figure S3G-H), were both decreased in BCG-stimulated samples compared to control. PGs were 291 not detected in the Guinea-Bissau *in vivo* cohort (Table S2). However, the time points were 292 markedly different – i.e., 4 weeks after BCG *in vivo* vs. 18 hours in vitro, suggesting an acute 293 inflammatory role for PGs rather than a contribution to a prolonged metabolic response.

294

295 **BCG-induced plasma lysophospholipids in vivo at 4 weeks post-vaccination correlated with** 296 **in vitro TLR agonist and mycobacterial antigen-induced cytokine/chemokine responses**

297

298 Lysophosphatidylcholine (LPC) is a critical component of low-density lipoprotein, and 299 high LPC levels have been associated with various diseases (Law et al., 2019; Okita et al., 1997). 300 LPC modulates immune responses by controlling distribution, trafficking, and activation of 301 leukocytes (Chiurchiù et al., 2018) and is a candidate sepsis treatment (Yan et al., 2004). In our 302 study, early BCG vaccination perturbed levels of several LPC components 4 weeks post-303 vaccination *in vivo* (Figure 6A-F). Early BCG administration was associated with significantly 304 increased plasma concentrations of LPC16:0 and LPC18:0 and decreased concentrations of 305 LPC18:2, -20:3, -20:4 and -22:6.

306

307 The immunogenicity of BCG in the Guinea-Bissau *in vivo* cohort, as measured by whole 308 blood cytokine responses to PPD antigen and TLR-agonist stimulation, has been previously 309 reported (Jensen et al., 2015). To study the relationship between BCG-induced LPLs *in vivo* 310 and recall cytokine production *in vitro*, we analyzed previously generated cytokine 311 measurements on PPD and other TLR agonist recall responses for the subset of newborn 312 participants included in our metabolomic and lipidomic studies. Relative to the delayed BCG 313 cohort, newborns who received early BCG demonstrated increased PPD-induced production of 314 TNF α (p=0.0072), IL5 (p<0.0001), IL6 (p=0.0229), IL17 (p<0.0001), and IFN γ (p<0.0001)
315 (Figure S4A-G, Table S6). Significant correlations were noted between concentrations of LF 315 (Figure S4A-G, Table S6). Significant correlations were noted between concentrations of LPC 316 species (LPC 14:0, 16:0, 17:0, 18:0, 18:1, 18:2, 20:1, 20:2, 20:4) and cytokines IL5, IL6, IL10, 317 TNFα, IL17 and IFNγ (Figure 6G-H). Multiple LPCs (LPC 22:5, 17:0, 16:1, 15:0) positively
318 correlated with TLR4- and TLR7/8-mediated IL6 production. while LPCs 20:1, 20:0, 18:0 and 318 correlated with TLR4- and TLR7/8-mediated IL6 production, while LPCs 20:1, 20:0, 18:0 and 319 16:0 negatively correlated with TLR2/1-mediated IL6 production. Multiple LPCs (LPCs 20:4, 320 20:0, 19:1, 17:0, 14:0) also positively correlated with TLR2/1-, TLR7/8-mediated as well as 321 PPD-induced IL10 production. In particular, LPC 18:0 was positively correlated with PPD-322 induced IL10 production. These observations raise the possibility that alterations in LPLs, lipids 323 with known roles in immune regulation and responses to mycobacterial infection (Lee et al., 324 2018), may contribute to BCG immunogenicity.

325

326 To determine the response to stimulation with BCG *in vitro*, we subjected WBA 327 supernatants to multiplex cytokine and chemokine profiling (Figures S1B and 1B). BCG 328 stimulation of cord blood for 18 hr significantly induced the production of multiple cytokines 329 and chemokines, resulting in a balanced Th1-, Th2-, and Th17-polarizing cytokine profile 330 (Figure S5A). Consistent with previously reported acute activation of BCG-induced Th1 331 responses (Angelidou et al., 2020a) and early proinflammatory bias (Freyne et al., 2018), the 332 addition of BCG to whole blood *in vitro* induced IL-1ß, a cytokine that may be important to 333 BCG vaccine immunogenicity (Scheid et al., 2018) and innate training that may contribute to 334 non-specific/pathogen-agnostic beneficial effects (Arts et al., 2018) (Figure S5B). BCG also 335 induced the production of anti-inflammatory IL-10 (Figure S5B). As expected, these plasma 336 cytokines were not detected *in vivo* at the 4-week time point, given likely normalization to 337 baseline 4-weeks after vaccination (Stenken and Poschenrieder, 2015).

338

339 **Comparison of BCG-induced metabolic profiles across cohorts demonstrates modulation of** 340 **common metabolomic pathways**

341

342 To validate metabolomic signatures of the BCG vaccine in early life, we compared the 343 Guinea-Bissau and Boston cohorts with another independent newborn group from the EPIC-001 344 study in The Gambia (West Africa) using high-throughput metabolomics. Newborns (n=27) were 345 assigned to either receive the Expanded Program on Immunization (EPI) vaccines (OPV, BCG, 346 and HBV) at birth or delayed during the first week of life to study the effect of vaccine responses 347 on early life immune ontogeny (Figure 1C, Figure S1C) (Lee et al., 2019). Peripheral blood was 348 collected at two time points: a pre-vaccination sample at the day of life 0 (DOL0; birth), then a 349 second sample randomized at either DOL1, DOL3, DOL7. All enriched metabolite sets 350 discovered in the EPI-vaccinated Gambia cohort were shared among the Guinea-Bissau and 351 Boston cohorts suggesting that BCG-induced metabolic pathways followed a consistent pattern 352 (Figure 7A, 7C, 7D). Shared sets of BCG-induced metabolic changes included sphingolipid 353 metabolism, glycine and serine metabolism, methionine metabolism, purine metabolism, galactose metabolism, bile acid biosynthesis, amino sugar metabolism, lactose synthesis, 355 spermidine and spermine biosynthesis, and betaine metabolism (Figure 7D). The variety and 356 abundance of such BCG-modulated pathways are consistent with newborns' complex metabolic 357 and bioenergetic needs. LPLs belonging to phospholipid biosynthesis metabolite enriched sets 358 demonstrated perturbation across all three cohorts. While a more significant number of 359 downregulated metabolites were noted following BCG-stimulation *in vitro*, both West African *in* 360 *vivo* cohorts (Guinea Bissau and The Gambia) displayed similar metabolic trends, suggesting 361 similar metabolome profiles within this geographic region (i.e., West Africa; Figure 7B). Of 362 note, ~70% of significant metabolites in Gambian neonates belonged to the lipid class (Table 363 S8), supporting a major lipid signature of BCG vaccination early in life. 364

- 365
- 366

367 **Discussion**

368

369 Herein we present the first characterization of BCG-induced changes to the human 370 newborn plasma metabolome. Prior studies of the neonatal plasma metabolome have used 371 umbilical cord blood for metabolomic profiling (Fanos et al., 2013; Mussap et al., 2013) due to 372 limitations in the number and quantity of neonatal blood draws. To our knowledge, the sole 373 exception is our prior study of immune ontogeny that assessed plasma metabolites from the 374 human peripheral newborn blood plasma (Lee et al., 2019). Herein, we employed plasma 375 metabolomics to define BCG-induced metabolic changes in three independent newborn cohorts, 376 two *in vivo* (Guinea Bissau and The Gambia; West Africa) and one *in vitro* (Boston, MA: USA). 377 To our knowledge, our effort represents the first application of metabolomics to characterize 378 vaccine action in newborns, who exhibit distinct immunity and are at the greatest risk of 379 infection (Whittaker et al., 2018).

380

381 Human *in vitro* assays are a promising approach to characterize vaccine action and 382 generate data with relevance *in viv*o (Dowling and Levy, 2014; Sanchez-Schmitz et al., 2018). 383 Using a whole blood stimulation assay, we were able to recapitulate metabolic changes induced 384 by early BCG vaccination and identify additional candidate biomarkers of early BCG 385 immunization in newborns. Systems vaccinology studies have demonstrated overlap between 386 vaccine-induced systems biology signatures *in vivo* and those detected by WBA *in vitro* (Diray-387 Arce et al., 2021; Lee et al., 2019; Li et al., 2017; Nakaya et al., 2016; Nakaya et al., 2011; White 388 et al., 2012). A recent study assessed the impact of neonatal BCG administration on clinical 389 outcomes and epigenetic and cytokine responses in peripheral blood mononuclear cells 390 (PBMCs). Still, it did not examine metabolomic signatures (Prentice et al., 2021). Neonates 391 typically exhibit Th2-polarized immune responses (Dela Pena-Ponce et al., 2017), but the live 392 attenuated BCG vaccine engages multiple PRRs and induces balanced Th1/Th2 responses in the 393 early life (Marchant et al., 1999; Sanchez-Schmitz et al., 2018). Given the vital role of 394 metabolism in immunity and the unique metabolic state of newborns, we sought to explore how 395 BCG given at birth affects the newborn plasma metabolome. We showed that neonatal BCG 396 vaccination perturbs plasma lipid pathways in a reproducible pattern. Interestingly, metabolic 397 changes correlated with *in vitro* cytokine and chemokine responses of whole blood to innate 398 (TLR agonist) and adaptive (PPD antigen) stimuli.

399

400 A remarkable feature of our results is that early administration of BCG appeared to re-401 model the plasma lipidome, shifting concentrations of LPLs such as LPCs and GPCs. LPCs are 402 quickly metabolized by lysophospholipases to GPCs, which could explain our observation of 403 decreasing plasma LPCs and increasing GPCs in our early BCG dataset (Figure 2C and 4G). 404 Interestingly, a consistent decrease in plasma GPCs has been observed in sepsis vs. non-infected 405 patients with systemic inflammatory response syndrome (SIRS)(Langley et al., 2013) while 406 exogenous stearoyl-GPC improved sepsis outcomes in mice (Yan et al., 2004). Our results thus 407 raise the possibility that BCG-induced increases plasma GPCs may contribute to pathogen-408 agnostic protection against sepsis and respiratory infections in early life.

409
410 Lipid metabolism is key to cell membrane structure and function, including in that of 411 leukocytes (Lochner et al., 2015), and has been proposed to contribute to vaccine-induced 412 epigenetic reprogramming of immune responses (Netea et al., 2016; O'Neill et al., 2016). We

413 noted that BCG immunization induced a decrease in plasma concentrations of most of the LPLs 414 detected. These findings were validated in our *in vitro* assay. Prominent among the plasma LPLs 415 whose concentrations changed after BCG administration were LPCs. Bioactive products of 416 phospholipase-mediated removal of fatty acids from phosphatidylcholine, LPCs are plasma 417 constituents that can act directly on cell membranes and signal via protein G protein-coupled 418 receptors or TLRs (Sharma et al., 2020), thereby exerting a range of immunologic effects 419 (Knuplez and Marsche, 2020; Sharma et al., 2020). LPCs such as LPC 18:1 and 16:0 can 420 modulate neutrophil reactive oxygen production (Ojala et al., 2007), promote TLR signaling, 421 enhance the generation of mature dendritic cells (DCs) from differentiating human monocytes as 422 well as enhance antigen-specific cytotoxic T cell and antibody responses *in vivo* (Knuplez and 423 Marsche, 2020; Perrin-Cocon et al., 2006). At baseline, newborn plasma contains relatively high 424 concentrations of LPC (20:4) and PC (36:4), but the plasma phospholipid profile changes 425 markedly over time in a manner dependent on the dietary fatty acid composition (Uhl et al., 426 2016). 427

428 In our study, BCG-induced changes in LPCs correlated with blood cytokine responses to 429 stimulation with multiple TLR agonists and mycobacterial antigen (PPD) (Figure 6G-6H). 430 Interestingly, potential pro-inflammatory effects of BCG vaccination may be counterbalanced by 431 enhanced production of LPC 16:0, an LPC that was increased in our *in vivo* cohort (Figure 6A). 432 LPC 16:0 can act as an "eat-me" signaling target, enhancing uptake of apoptotic cells (Soehnlein 433 et al., 2009), as well as regulating the production of TNF and nitric oxide (NO)(Yan et al., 434 2004). The kinetics of BCG-induced LPC 16:0 production remains to be defined, but to the 435 extent that our *in vitro* studies reflect kinetics *in vivo*, they may not initiate until after the first 436 day of vaccination. LPC can function as a dual-activity ligand molecule triggering a classical 437 proinflammatory phenotype by activating TLR4 and TLR2/1 mediated signaling on human 438 embryonic cells (Carneiro et al., 2013). LPC species are also regulators of the innate immune 439 response preventing excess inflammation and limiting mycobacterial survival in the host (Lee et 440 al., 2018). Dual immunologic roles of LPCs have also been observed in mice wherein LPC 441 increased production of antimicrobial agents ROS and NO while inducing IL10 in Mtb-infected 442 macrophages, thereby enhancing macrophage-based host defense while avoiding excessive 443 production of pro-inflammatory cytokines (Lee et al., 2018). Of note, LPCs have been explored 444 as novel immunomodulatory agents. Indeed, systemic administration of LPC protected mice 445 against experimental sepsis-induced lethality, enhanced clearance of bacteria, and inhibited the 446 production of pro-inflammatory cytokines TNF α and IL1 β (Lee et al., 2018). Overall, BCG modulation of plasma LPCs may fine-tune immune responses to shape cellular immunity to modulation of plasma LPCs may fine-tune immune responses to shape cellular immunity to BCG 448 antigens, enhance antimicrobial activity and avoid anti-inflammatory responses.

449

450 In addition to our observations regarding BCG-induced changes in LPCs, BCG uptake by 451 the host can trigger several other lipid pathways, such as $PGE₂$ production from the eicosanoids 452 (Almeida et al., 2009). Eicosanoids regulate macrophage death and participate in several cellular 453 pathways that either promote or inhibit inflammation (Behar et al., 2010). PGE₂ induces 454 apoptosis of infected macrophages, a process that triggers the activation of DCs and subsequent 455 enhancement of T cell responses crucial for optimal vaccine effectiveness and protection (Behar 456 et al., 2010). In stark contrast to BCG (*M. bovis*) and attenuated Mtb strains, virulent Mtb strains 457 are weaker $PGE₂$ inducers and induce necrosis of infected macrophages, enabling innate immune 458 evasion and delay in initiation of adaptive immunity (Behar et al., 2010; Chen et al., 2008).

459 Upon stimulation of human newborn blood with BCG *in vitro*, we noted a significant increase in 460 PGE₂ and arachidonate acid (FFA (20:4)), an immediate precursor of prostaglandin E₂ (PGE₂). 461 Possibly due to their short half-life, PGs were not detected 4 weeks after BCG immunization in 462 the Guinea-Bissau *in vivo* cohort.

463

464 Differences in FFA composition between conditions (BCG stimulated vs. control) for 465 both our *in vivo* and *in vitro* cohorts were consistent with previous studies suggesting vaccine-466 induced alterations in membrane remodeling and lipid metabolism (Diray-Arce et al., 2020; Li et 467 al., 2017). Alternatively, they may reflect nutritional differences or represent the distinct 468 metabolic needs of the newborn between DOL0 when cord blood was obtained for the *in vitro* 469 assay and DOL28, the time point at which peripheral blood was collected from the *in vivo* cohort 470 (Conti et al., 2020).

471 472 Vaccine interactions are increasingly recognized in systems vaccinology, and a growing 473 body of literature suggests that the nature of the vaccine stimulus (live attenuated vs. killed or 474 inactivated), as well as the order in which vaccines are administered, matters for their net off-475 target effects (Blok et al., 2020; Clipet-Jensen et al., 2021; Higgins et al., 2016; Li et al., 2020; 476 Sorup et al., 2016; Thysen et al., 2019; Welaga et al., 2017). In our cohort, early BCG was given 477 together with OPV, another live attenuated vaccine given at birth in developing countries, shown 478 to confer mortality benefits from infectious causes (Andersen et al., 2018; Lund et al., 2015). 479 Even though BCG and OPV could not be studied separately, analysis of the parent trial with 480 complete follow-up vs. after censoring for national OPV campaigns yielded similar mortality 481 benefits for the early BCG (Biering-Sorensen et al., 2017). Delayed BCG was given with OPV 482 and Penta, a combination of inactivated vaccines including DTP, per the GB national 483 immunization schedule. Studies comparing the clinical and immunologic effects of different 484 sequences of vaccines are needed to assess the off-target effects of EPI vaccinations, avoid any 485 undesirable negative effects on mortality and fully leverage beneficial pathogen-agnostic effects 486 for clinical benefit.

487

488 BCG strain differences may also partially account for some differences observed between 489 the in vitro (BCG-Tice) and *in vivo* (BCG-SSI) cohorts (Angelidou et al., 2020b). However, the 490 effect of BCG on LPL plasma concentrations was similar (consistent decrease both *in vivo* and in 491 vitro) regardless of strain. Even though our study was not specifically designed to address BCG 492 strain differences, future studies should make an effort to incorporate in vitro testing of BCG 493 strains administered *in vivo*. In addition, human vaccine trials testing BCG-induced pathogen-494 specific and -agnostic protection should adopt study designs amenable to head-to-head strain 495 comparisons in order to detect actionable differences in vaccine efficacy and immune signatures 496 (Comstock, 1988).

497

498 Our study features a number of strengths, including (a) a focus on human immune 499 responses to BCG, one of the most commonly given vaccines across the globe that is critical to 500 newborn health and is also being studied for potential benefits in protecting against viral 501 infection and auto-immune diseases (Arts et al., 2018; Diray-Arce et al., 2020; Faustman, 2020; 502 Moorlag et al., 2020); (b) novel application of state-of-the-art plasma metabolomic and lipidomic 503 technologies to characterize BCG responses in vulnerable newborn cohorts in low income

504 settings (West Africa); (c) study of multiple independent cohorts *in vivo* and *in vitro*; (d)

505 identification of lipids and in particular LPLs/LPCs as key metabolites altered by BCG; (e)

506 significant correlation of LPCs with innate (TLR agonist) and adaptive (PPD) cytokine

507 responses; and (f) validation of BCG-induced metabolic signatures across three independent

508 cohorts in West Africa (Guinea Bissau and The Gambia; *in vivo*) and North America (Boston,

509 USA; *in vitro*). Overall, by demonstrating the applicability of metabolomics in vulnerable

510 newborns from resource-poor settings and defining novel candidate biomarkers that may

- 511 contribute to BCG's protective effects, our study represents an important advance in the field of 512 neonatal systems vaccinology.
- 513

514 Our study also has several limitations, including (a) limited blood sample volumes from 515 newborns necessitating pooling of samples by sex and treatment prior to metabolomic and 516 lipidomic analyses, (b) a relatively high neonatal mortality in the early BCG trial so that some 517 selection bias may have occurred, as we were only able to assess those who survived to 4 weeks 518 of age, and (c) a possibility for false-positive findings for the Guinea-Bissau samples, as we 519 chose not to adjust for multiple comparisons (Rothman, 1990). Regarding the latter, many false 520 discovery rate (FDR) methods are considered too stringent for metabolomics analysis due to the 521 high correlation and redundancy between metabolite features, resulting in a lack of agreed-upon 522 standards in the field. We mitigated FDR concerns by validating our findings using a human 523 newborn *in vitro* system and cross-comparison with a second independent Gambian newborn 524 cohort studied *in vivo* to model BCG-induced metabolic shifts. Finally, BCG may induce a wider 525 variety of metabolic pathways, and future studies are required to identify their significance and 526 functional relation to immunogenicity and protection, as well as their correlation with other 527 systems biology ("omic") measures such as systems serology (Ackerman et al., 2017).

528

529 In summary, we have demonstrated the feasibility of assessing neonatal plasma 530 metabolites in a resource-poor setting to identify vaccine-induced metabolic pathways in this 531 study. BCG-induced alterations in LPLs, especially LPCs known to have roles in immune 532 regulation and response to infection (Carneiro et al., 2013), were particularly pronounced and
533 correlated with innate (TLR agonist) and adaptive (PPD) cytokine responses, suggesting that 533 correlated with innate (TLR agonist) and adaptive (PPD) cytokine responses, suggesting that 534 LPCs may contribute to BCG immunogenicity. These lipid biomarkers are novel candidates for 535 correlates of protection that may contribute to BCG's specific (vs. TB) and heterologous 536 protective effects. Overall, our study suggests that vaccine-induced metabolites, and especially 537 lipids, may be relevant biomarkers of vaccine immunogenicity that may help inform more 538 precise discovery and development of vaccines.

- 539
- 540
- 541

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2021.12.03.21267251;](https://doi.org/10.1101/2021.12.03.21267251) this version posted December 5, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted

542 **STAR^{***I***}Methods 543 • KEY RES** 543 • **KEY RESOURCES TABLE** 544 • **CONTACT FOR REAGENT AND RESOURCE SHARING** 545 • **EXPERIMENTAL MODEL AND SUBJECT DETAILS** 546 o **Newborn cohort characteristics and sample preparation** 547 Guinea-Bissau *in vivo* infant cohort receiving BCG at birth or delayed.
Boston newborn cohort stimulated *in vitro* with BCG or saline control. 548 Boston newborn cohort stimulated *in vitro* with BCG or saline control.
 Gambian *in vivo* cohort receiving EPI vaccines (BCG, HBV, OPV) at 549 Gambian *in vivo* cohort receiving EPI vaccines (BCG, HBV, OPV) at birth or delayed 550 birth or delayed 551 • **METHOD DETAILS** 552 o **Global Untargeted Metabolomics Profiling** 553 o **Complex Lipid Platform Lipidomics** 554 o *In vitro* **stimulation of blood derived from early- vs. delayed-BCG infants** 555 **with TLR agonists and mycobacterial antigen purified protein derivative** 556 **(PPD) to assess cytokine responses** 557 • **QUANTIFICATION AND STATISTICAL ANALYSIS** 558 559 560 **KEY RESOURCES TABLE**

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2021.12.03.21267251;](https://doi.org/10.1101/2021.12.03.21267251) this version posted December 5, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted

> chemokines and hematopoietic factors

561 562

563 564 **CONTACT FOR REAGENT AND RESOURCE SHARING**

565 Requests for information regarding reagents and resources should be directed to and will be

566 fulfilled by correspondence to Dr. Ofer Levy MD, Ph.D., Director of the *Precision Vaccines*

567 *Program* at Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA 568 (ofer.levy@childrens.harvard.edu).

569

570 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

571 **Newborn cohort characteristics and sample preparation**

572 *Guinea-Bissau study of infants receiving BCG at birth or delayed*. A randomized-controlled trial 573 (RCT) of early BCG vaccination in low birth weight (<2.5 kg) neonates was conducted by the 574 Bandim Health Project (BHP) in Guinea-Bissau, West Africa, with neonatal mortality as the 575 primary outcome. A sub-group of the infants participating in the RCT was invited to participate 576 in an immunological study during 2011-2012 to assess the effect of early BCG vaccination on *ex* 577 *vivo* cytokine responses to PPD and innate agonists. Previous publications have described the 578 details of the enrollment and randomization procedures of the RCT (Biering-Sorensen et al., 579 2017) and the blood collections and sample processing of the immunological sub-group study

580 (Jensen et al., 2015). In brief, newborns eligible for participation in the RCT were low birth

581 weight (<2500 g), not overtly ill, had not received BCG, and had no malformations at the time of

582 enrollment. Informed consent was obtained from the mothers of the recruited newborns. The 583 BCG RCT and the immunological sub-study were approved by the National Committee on

584 Health Ethics of the Ministry of Health in Guinea-Bissau, and a consultative approving statement 585 was obtained from the Danish National Committee on Biomedical Research Ethics. The BCG 586 trial was registered with clinicaltrials.gov, number NCT00625482. Details are illustrated in Fig

- 587 S1.
- 588

589 Upon enrollment, the infants were randomized (1:1) to an infant dose of BCG-SSI 590 (Statens Serum Institut, SSI; Copenhagen, Denmark) or delayed BCG immunization at six 591 weeks. Infants assigned to early BCG were vaccinated intra-dermally in the upper deltoid region 592 with 0.05 ml BCG vaccine (strain 1331, SSI, Copenhagen, Denmark) by trained nurses. Infants
593 assigned to the control group were treated according to local practice such that vaccination was assigned to the control group were treated according to local practice such that vaccination was 594 postponed until they reached >2.5 kg in weight, or more commonly when they presented for their 595 first Penta vaccine (DTP-HBV-Hib) recommended at six weeks of age. The Pentavalent vaccine 596 given to infants was either *Easyfive* (Panacea Biotech India), *Quinvaxem* (Berna Biotech Korea 597 Corp) or *Pentavac* (Serum Institute of India) for this randomized control study. All infants 598 received oral polio vaccine (OPV) at birth. For enrollment into the immunological sub-group 599 study, infants were visited at home by the study team four weeks after randomization to BCG or 600 no BCG. For logistical reasons, infants living in Bissau City and nearby suburbs were given 601 priority. After providing informed consent, the mother was interviewed about the health status of 602 her child, and the length, weight, and mid-upper arm circumference of the child were measured. 603 Clinical data on sex, weight, BCG scar, PPD testing results were also available. Scar size was 604 defined as the average of two perpendicular diameters on the scar formed at the injection site. 605 Local reaction to the BCG vaccine was assessed and measured. Blood was collected by heel 606 puncture into a heparin-coated tube.

607

608 For this current study, we included plasma samples from newborns randomized within 609 the first week of life. However, samples from infants in the delayed BCG group who had 610 received BCG before phlebotomy, who were Penta-vaccinated, or had hemolyzed samples were

611 excluded. Biosamples were shipped on dry ice to the *Precision Vaccines Program* (Boston, MA,

- 612 USA) for subsequent metabolomic assays (Figure S1). *In vitro* cytokine assays were conducted
- 613 as outlined below. For metabolomic and lipidomic assays, samples were selected per sex and
- 614 treatment based on the following criteria: 1) Exclusion criteria included a history of vomiting or
- 615 diarrhea per mother's report, hemolyzed samples, or limitation of available sample volume (i.e.,
- 616 \leq 20 μ L); 2) Inclusion: To overcome the limitation of sample volumes, ten newborn samples 617 stratified by sex and treatment were pooled prior to shipment to *Metabolon* (Durham, North
- 618 Carolina, USA) for mass spectrometry-based metabolomics and lipidomic assays. These samples
- 619 were matched with their clinical information. To gain insight into the impact of BCG
- 620 immunization on both innate and adaptive immunity, blood was collected at four weeks and
- 621 stimulated *in vitro* with vehicle control (Roswell Park Memorial Institute medium, RPMI), *Toll*-
- 622 like receptor (TLR) agonists or PPD. After incubation, supernatants were collected and
- 623 cryopreserved prior to batch measurement of cytokines by multiplex assay. Clinical data with
- 624 corresponding *in vitro* stimulated blood derived from the early BCG (n=60) and control infants
- 625 (delayed BCG, $n=60$) included in this metabolomics study were reanalyzed and yielded
- 626 comparable baseline clinical characteristics (Table S1).
- 627
- 628 *Boston newborn cohort stimulated in vitro with BCG or saline control*. Coded human cord blood
- 629 samples (n=12) were collected from healthy term $(\geq 37$ weeks' gestation) elective cesarean deliveries in accordance with approved protocols from the Institutional Review Boards of the
- deliveries in accordance with approved protocols from the Institutional Review Boards of the
- 631 Beth Israel Deaconess Medical Center, Boston, MA, and The Brigham & Women's Hospital,
- 632 Boston, MA. Blood samples were anti-coagulated with 15 U/ml of clinical-grade pyrogen-free
- 633 heparin sodium and assayed within 4h. Blood collected was diluted 1:1 in RPMI medium and 634 stimulated in 96 well U-bottom plates with BCG-Tice (Merck, 1:1000 vol/vol) and saline vehicle
- 635 (1:1000 vol/vol). BCG-Tice was reconstituted with the provided diluent per manufacturer's
- 636 instructions and used within 4-6h after reconstitution. After 18 hr incubation at 37**°**C,
- 637 supernatants (90% plasma vol/vol) were collected and stored at -80°C. Two plasma aliquots were
- 638 submitted to *Metabolon, Inc* for metabolomics profiling and complex lipids platform. BCG-only
- 639 controls were included (High and Low concentration). For these samples, the 'High'
- 640 concentration corresponded to the reconstitution of the BCG vaccine in 1 ml saline, and the
- 641 'Low' concentration corresponded to a 1:1000 dilution. Three replicates of high concentration
- 642 and five replicates of low concentration were processed for each data stream.
- 643
- 644 *EPIC-001 cohort. Gambia in vivo newborn cohort EPI-vaccinated (BCG, HBV, OPV) at birth or* 645 *delayed-vaccinated* (Lee et al., 2019). As part of the EPIC-001 clinical study, pregnant mothers 646 were enrolled following informed consent. On the day of birth (DOL 0), peripheral blood 647 samples were obtained from all newborns pre-vaccination. These newborns, according to group 648 assignment, were then either immunized with EPI vaccines (oral polio vaccine (OPV), BCG and 649 Hepatitis B) at birth or after a delay. A follow-up blood sample collection was obtained from all 650 infants at either DOL 1, DOL 3, or DOL 7 with a maximum of two peripheral blood collections 651 per participant in the first week of life (Figure 1C, Figure S1C). Plasma preparation and 652 metabolomics assay for this cohort have been previously described (Lee et al., 2019).
- 653
- 654 **METHOD DETAILS**

655 **Global Untargeted Metabolomics Profiling**

656 Plasma metabolite profiling was conducted by Metabolon using in-house standards 657 (Evans et al., 2009; Long et al., 2017). Each plasma sample was stored at -80° C and accessioned 658 into the Metabolon Laboratory Information Management System (LIMS). To enable an 659 association with the original source identifier and for tracking purposes, each sample was 660 assigned a LIMS unique identifier. Samples were extracted and prepared for analysis using 661 Metabolon's solvent extraction method (Evans, 2008). Recovery standards were added to the first 662 step in the extraction process to ensure proper quality control. Protein was removed by methanol 663 precipitation under vigorous shaking for 2 mins (Glen Mills GenoGrinder 2000) then by 664 centrifugation. The supernatants were divided into five fractions: one for analysis by UPLC-665 MS/MS with positive ion mode electrospray ionization, one for analysis by UPLC-MS/MS with 666 negative ion mode electrospray ionization, one for LC polar platform, one for analysis by GC-667 MS, and one sample was reserved for backup. Samples were placed briefly on a TurboVap® 668 (Zymark) to remove the organic solvent. For LC, the samples were stored overnight under 669 nitrogen before preparation for analysis. For GC, each sample was dried under vacuum 670 overnight before preparation for analysis (Lawton et al., 2008).

671

672 **Complex Lipids Platform Lipidomics**

673 The Complex Lipid Panel (CLP) lipidomics data is a non-chromatographic, infusion-674 based targeted discovery platform for a defined list of lipid species. This method does not 675 produce chromatographic peaks but analyzes a continual stream of lipid extract. No annotation/ 676 identification of compounds is required because the methodology uses a combination of 677 empirically determined Ion Mobility properties and specifically designed multiple reaction 678 monitoring (MRM) transitions to uniquely target each lipid species during the analytical process. 679 Lipids were extracted from *in vivo* Guinea-Bissau newborn plasma samples and from cord blood 680 plasma after *in vitro* BCG stimulation in the presence of deuterated internal standards using an 681 automated butanol-method (BUME) extraction (Lofgren et al., 2012). Extracts were dried under 682 nitrogen and reconstituted in ammonium acetate dichloromethane: methanol then transferred to 683 vials for infusion-MS analysis employing a Shimadzu LC with nano PEEK tubing and the Sciex 684 SelexIon-5500 QTRAP. Samples were analyzed via both positive and negative mode 685 electrospray. The 5500 QTRAP was operated in multiple reaction monitoring modes (MRM) 686 with a total of $>1,100$ MRMs.

687

688 **TLR agonist- and PPD antigen- induced cytokine responses in blood derived from early vs.** 689 **delayed BCG immunized newborns**

690 To assess the effect of BCG administration to Guinea-Bissau study participants on 691 subsequent *in vitro* TLR agonist- (innate) and PPD antigen (adaptive)- induced cytokine 692 responses, heparinized blood collected at 4 weeks was diluted 1:9 with RPMI-1640 void of L-693 Glutamine (Gibco, Life Technologies Europe BV) supplemented with Pyruvate 1 mM (Na-694 pyruvate, Lonza; Copenhagen, Denmark) and L-Glutamine–Penicillin–Streptomycin 1X (Gibco, 695 Life Technologies). *In vitro* re-stimulation with phorbol 12-myristate 13-acetate (PMA) (100 696 ng/mL; Sigma-Aldrich) and ionomycin (1 µg/mL) (Sigma-Aldrich) as a positive control; PPD 697 antigen from *M. tuberculosis* (Statens Serum Institut, Copenhagen, Denmark) (10 µg/mL) to 698 assess the mycobacterial specific response; lipopolysaccharide (LPS) (10 ng/mL) (Sigma-
699 Aldrich) [a Toll-like receptor (TLR)4 agonist]; (S)-(2,3-bis(palmitovloxy)-(2-RS)-propyl) 699 Aldrich) [a Toll-like receptor (TLR)4 agonist]; (S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-700 palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys4-OH,trihydrochloride (Pam3CSK4) (1 µg/mL) [a TLR2/1 701 agonist] (InvivoGen); Thiazoloquinoline Compound (CL075) (1 µg/mL) [a TLR8/7 agonist]

702 (InvivoGen) employed 200 μL round-bottom microtiter plates (NUNC; Roskilde, Denmark) in a
703 37°C humidified incubator with 5% CO₂ for 24 hr to assess the mycobacterial specific response

703 37°C humidified incubator with 5% CO_2 for 24 hr to assess the mycobacterial specific response
704 together with RPMI control. After 24h of culture, supernatants were collected and stored at <

together with RPMI control. After 24h of culture, supernatants were collected and stored at \lt

705 −70°C until analysis. Cytokine concentrations were measured at SSI, employing an

706 immunobead-based multiplexed assay as previously described (Skogstrand et al., 2005).

707 708

709 **QUANTIFICATION AND STATISTICAL ANALYSIS**

710 **Global Metabolomics and Lipidomics Analysis**

711 For metabolomics, compounds were identified by comparison to Metabolon library 712 entries of standard metabolites (Evans et al., 2009). Biochemical identification was based on 713 three criteria: retention index (RI) within a narrow RI window of the proposed identification, 714 accurate mass match to the library ± 10 ppm, and the MS/MS forward and reverse scores
715 between the experimental data and authentic standards. The MS/MS scores were based on between the experimental data and authentic standards. The MS/MS scores were based on a 716 comparison of the ions present in the experimental spectrum to the ions present in the library 717 spectrum. Exact molecular mass data from redundant m/z peaks corresponding to the formation 718 of different parent and product ions were first used to help confirm the metabolite molecular 719 mass. Metabolon's *MassFragment*[™] application manager (Waters MassLynx v4.1, Waters 720 Corp.; Milford, USA) facilitated the MS/MS fragment ion analysis process using peak-matching 721 algorithms and quantified using area-under-the-curve. All identified metabolites were 722 categorized as Level 1 metabolites according to reporting standards set by the Chemical Analysis
723 Working Group of the Metabolomics Standards Initiative (Members et al., 2007: Spicer et al., 723 Working Group of the Metabolomics Standards Initiative (Members et al., 2007; Spicer et al., 724 2017; Sumner et al., 2007), and appropriate orthogonal analytical techniques were applied to the 725 metabolite of interest and to a chemical reference standard. Level 1 identification included 726 analyses of two or more orthogonal properties of an authentic chemical standard. Metabolites 727 identified in our study had a corresponding accurate mass confirmed via MS with retention 728 index, chemical, and composition ID, and those with an exact matching mass were reported.

729

730 Raw data were measured based on LC-MS peak areas proportional to feature 731 concentration. Quality control measures were performed by the following steps: 1. Missingness 732 assessment of the data; 2. Missing values were imputed with half the minimum detected level for 733 a given metabolite; 3. Metabolites with an interquartile range of 0 and xenobiotics were excluded 734 from the analysis; 3. Features (relative peak intensities) were log-transformed, normalized then 735 pareto-scaled to reduce variations. 4. Visual inspection with Principal Component Analysis 736 (Figure S2A-J). Statistical analyses for univariate, chemometrics, and clustering analysis used in-737 house algorithms, R statistical packages, and *MetaboAnalyst 4.0* (Xia et al., 2015; Xia and 738 Wishart, 2016). Metabolite super pathways consist of biochemical metabolite annotation 739 corresponding to their general metabolic class, including amino acid, carbohydrate, lipid, 740 nucleotide, energy, peptide, cofactors and vitamins, and xenobiotics. We filtered out the 741 xenobiotics to only focus on endogenous metabolites. Each super pathway is further subdivided 742 into ≥2 more specific sub-pathways. The hypergeometric test in *MetaboAnalyst* was specified for 743 the over-representation analysis and relative-betweenness centrality for the pathway topology 744 analysis. 745

746 Pathway analyses and visualization employed *MetaboAnalyst* 4.0 Metabolite Set 747 Enrichment Analysis (MSEA) based on the KEGG Pathway (www.genome.jp/kegg/) and the

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2021.12.03.21267251;](https://doi.org/10.1101/2021.12.03.21267251) this version posted December 5, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted

748 Human Metabolome Database Version 3.6 (HMDB). MSEA identifies biologically meaningful 749 patterns in changes in metabolite concentrations by evaluating the significance individually 750 under each condition. Metabolites that reached significance (alpha=0.05) were combined in an 751 effort to detect meaningful patterns and investigate if a group of functionally related metabolites 752 was enriched. This method can identify subtle but consistent changes among metabolites that 753 may not be detected by conventional approaches (Jia et al., 2014; Xia and Wishart, 2011, 2016). 754 To enhance the robustness of our findings despite small effect sizes, we have focused on 755 pathways that are perturbed after comparison to their own controls across multiple cohorts *in* 756 *vivo* and *in vitro*. Statistical modeling was based on data distribution for each dataset. For plasma 757 metabolomic data from Guinea-Bissau *in vivo* samples, early and delayed BCG groups were 758 compared using unpaired t-test with Welch's correction. For the Gambia cohort, the peripheral 759 blood was profiled twice over the first week of life at DOL0 and at a second point at either 760 DOL1, 3, or 7. Univariate analyses were performed by analyzing paired differences per 761 participant, referred to as indexing. The analysis then proceeds by looking for differences 762 between treatments (delayed vs. EPI-vaccinated) rather than DOL.

763

764 For lipidomics, individual lipid species were quantified by comparing the ratio of the 765 signal intensity of each target compound to that of its assigned internal standard, then 766 multiplying by the concentration of internal standard added to the sample. Lipid class 767 concentrations were calculated from the sum of all molecular species within a class, and fatty 768 acid compositions were determined by calculating the proportion of each class comprised of 769 individual fatty acids. Of note, some of the same lipids detected in both platforms are named 770 differently due to conventions employed when the libraries for each platform were initially
771 developed $(e.g., 1-palmitoyl-GPC (16:0)$ in Global and LPC $(16:0)$ in CLP). Additionally, s developed (*e.g.*, 1-palmitoyl-GPC (16:0) in Global and LPC (16:0) in CLP). Additionally, some 772 isomers can be resolved on the Global platform (e.g., 1-oleoyl-GPC (18:1) and 2-oleoyl-GPC 773 (18:1)) while CLP reports the total of both (LPC 18:1). Missing values were imputed by 774 assigning them the minimum observed value for each compound. A similar approach used for *in* 775 *vivo* and *in vitro* metabolomics, namely log-transformation and modeling, was applied to identify 776 lipids that differed significantly between experimental groups. The *Surveyor* program was 777 employed for data organization and visualization of the fatty acids measured. Statistical analyses 778 for metabolomics and lipidomics employed R version 3.4.1. Comparisons with $p<0.05$ were
779 considered statistically significant with figure asterisks denoting level of significance (*p<0. considered statistically significant with figure asterisks denoting level of significance ($p<0.05$; 780 **p<0.01; ***p<0.001). Lipid species coverage and concentrations for *in vivo* and *in vitro* 781 studies are further described in Tables S9 and S10.

782

783 **Targeted Assays**

784 Plasma cytokine and chemokine concentrations were measured by multiplex assay, using 785 a Flexmap 3D system with Luminex xPONENT software version 4.2 (Luminex Corp.; Austin, 786 TX, USA). Cytokines and chemokines were measured using Milliplex Analyst software (v. 787 3.5.5.0, Millipore). Infant blood from the Guinea Bissau infant cohort was diluted and stimulated 788 *in vitro* with PPD or TLR agonists and cytokine and chemokine production measured as 789 previously described (Jensen et al., 2015). Cytokine and chemokine production from blood 790 derived from the subset of newborn participants included in our metabolomics and lipidomics
791 study was analyzed using an unpaired Wilcoxon Rank-sum Test. Comparisons with p<0.05 we study was analyzed using an unpaired Wilcoxon Rank-sum Test. Comparisons with $p<0.05$ were 792 considered statistically significant with figure asterisks denoting level of significance (*p<0.05; 793 $*p<0.01$; $**p<0.001$). Data are depicted as medians.

794 For the Boston cohort, a heatmap was generated, and treatment groups were compared 795 using two-sample t-tests with Benjamini, Krieger, and Yekutieli correction by comparing BCG-796 stimulated vs. vehicle control conditions from the same participants. Individual metabolites were 797 compared using a repeated-measures approach (Wilcoxon matched-pairs rank-sum test). 798 Comparisons with p<0.05 were considered statistically significant with figure asterisks denoting 799 level of significance (*p<0.05; **p<0.01; ***p<0.001). Data are shown as means ±SEM.

800

801 **Data Deposition**

802 Data files for metabolomics and lipidomics were deposited in ImmPort under accession numbers: 803 SDY1376 and SDY1709.

804

805 **Supplemental Information**

- 806 Supplemental information includes five figures and ten tables.
- 807

808 **Author Contributions**

809 Conceptualization: JDA, CB, OL; Clinical: JDA, KJ, BK, CB; Methodology: JDA, SvH, MP;

- 810 Formal Analysis, JDA, RK, JLS, AO; Writing-Original Draft: JDA, KJ, AA, GC; Writing-
- 811 Review & Editing: AA, RK, SvH, HS, JLS, AO, BK, TK, CB, OL; Resources: OL; Supervision:
- 812 OL; Funding Acquisition: OL.
- 813

814 **Acknowledgments**

815 We thank the participant families, nurses, and physicians of the Bandim Health Project

816 for enabling sample collection. We appreciate the Medical Research Council Gambia team for

817 recruitment, enrollment, and acquisition of samples. We also thank the Departments of Newborn

- 818 Medicine at the Brigham and Women's Hospital and Beth Israel Deaconess Medical Center for
- 819 cord blood collection. We thank Dr. Karen Pepper of MIT for providing valuable feedback and
- 820 editing the manuscript, Kristin Johnson of Boston Children's Hospital for illustrations, Sofia 821 Vignolo, Tanzia Shaheen, Annmarie Hoch for data deposition, and Diana Vo for programmatic
- 822 support. The European Research Council supported the randomized trial of BCG to CB (starting
- 823 grant ERC-2009-StG-243149), the Danish National Research Foundation (grant DNRF108 to
- 824 Research Center for Vitamins & Vaccines), and DANIDA, European Union FP7, and
- 825 OPTIMUNISE (grant Health-F3-2011–261375 to the Bandim Health Project); the
- 826 immunological sub-group study of early BCG vaccination was supported by Novo Nordisk
- 827 Foundation and a Ph.D. scholarship grant from University of Southern Denmark to KJ; KJ is
- 828 supported by a grant from Novo Nordisk Foundation (grant NNF14OC0012169).
- 829 This study was supported by the National Institute of Health/National Institute of Allergy &
- 830 Infectious Diseases Human Immunology Project Consortium Grant U19AI118608 and
- 831 Molecular Mechanisms of Combinations Adjuvants Grant U01 AI124284, as well as the BCH
- 832 *Precision Vaccines Program*. AA and OL were supported in part via the Mueller Health 833 Foundation.
- 834

835 **Declaration of Interests**

- 836 O.L is a named inventor on several Boston Children's Hospital patents relating to human 837 microphysiologic assay systems and vaccine adjuvants. S.M and G.M are employees of
- 838 Metabolon Inc. The other authors declare no competing financial interests.
- 839

840 **Figure Titles and Legends**

841 **Graphical abstract:**

842 **BCG vaccination perturbs metabolic pathways** *in vivo* **and** *in vitro***.**

843 Vaccines have traditionally been developed empirically, with limited insight into their 844 impact on molecular pathways. Metabolomics provides a new approach to characterizing vaccine

845 mechanisms but has not yet been applied to human newborns, who are at the highest risk of 846 infection and receive the most vaccines. Bacille Calmette-Guérin (BCG) prevents disseminated

- 847 mycobacterial disease in children and can induce broad protection to reduce mortality due to
- 848 non-TB infections. Underlying mechanisms are incompletely characterized. Employing mass
- 849 spectrometry-based metabolomics, we demonstrate that early BCG administration alters the
- 850 human neonatal plasma metabolome, especially lipid metabolic pathways such as
- 851 lysophosphatidylcholines (LPCs), both *in vivo* and *in vitro*. Plasma LPCs correlated with both
- 852 innate TLR-mediated and PPD antigen-induced cytokine responses suggesting that BCG-induced
- 853 lipids might contribute to the immunogenicity of this vaccine. Vaccine-induced metabolic
- 854 changes may provide fresh insights into vaccine immunogenicity and inform the discovery and
- 855 development of early life vaccines.
- 856

857 **Figure 1: Schematic of** *in vivo* **(A),** *in vitro* **(B), and validation cohort (C) for BCG** 858 **vaccination experimental setup.**

- 859 (A)Study design and participant plasma biosample flow chart. Low birth weight newborns in 860 Guinea-Bissau were assigned to delayed BCG (catch-up BCG after blood collection) or 861 early BCG (vaccinated with BCG at birth). In an immunological study nested within the 862 trial, capillary blood samples were collected four weeks after randomization to 863 investigate the effect of BCG on TLR agonist-induced and PPD antigen recall cytokine 864 responses. After the primary analyses (Jensen et al., 2015), plasma biosamples of 865 sufficient volume were utilized for subsequent metabolomic and lipidomic assays. To 866 ensure sufficient sample volume for robust metabolite detection, metabolomics (Q 867 Exactive, Thermo Scientific, Metabolon Inc; Durham, NC) and complex lipid panel 868 lipidomics (CLP, Metabolon Inc) were conducted on pooled plasma from $N = 10$ 869 newborns of the same sex and vaccine treatment.
- 870 (B) To further assess BCG's impact on the plasma metabolome, we modeled BCG vaccine 871 responses in vitro in cord blood from a cohort of newborns in Boston, USA. Similarly, 872 supernatants from these in vitro stimulated samples were subjected to high throughput 873 metabolomic, lipidomic, and cytokine/chemokine assays, and results indexed to the same 874 participant's vehicle (saline) control.
- 875 (C) For validation purposes, we compared the metabolomics profile of Guinea-Bissau *in vivo* 876 and Boston *in vitro* cohorts with another independent newborn group from The Gambia 877 (West Africa)(Lee et al., 2019). Newborns were assigned to either receive the Expanded 878 Program on Immunization (EPI) vaccines (OPV, BCG, and HBV) at birth or delayed 879 during the first week of life to study the effect of vaccine responses on early life immune 880 ontogeny. Paired samples were analyzed by indexing their DOL0 (day of birth) samples 881 and a follow-up timepoint at DOL1, DOL3, or DOL7. Regardless of their timepoint 882 assignment, the newborns were combined into their assigned treatment groups (EPI-883 vaccinated vs. delayed-vaccinated) for the purposes of analysis.
- 884

885 **Figure 2: BCG immunization perturbed the human neonatal plasma metabolome.**

931 **Figure 4: Plasma lipidomics reveals biomarkers of neonatal BCG vaccination.**

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2021.12.03.21267251;](https://doi.org/10.1101/2021.12.03.21267251) this version posted December 5, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted

978 number of hits by the expected number of hits of the overrepresented pathway. MSEA 979 calculates a hypergeometric test score employing a cumulative binomial distribution

- 980 based on the probability of seeing at least a particular number of metabolites with the
- 981 biological term of interest in a given compound list.
- 982 (D)The volcano plot illustrated BCG-induced changes in metabolites as compared to vehicle 983 control. Red color represents significant (*P* < 0.05), pink marginally significant (*P* < 0.1 984 to $P > 0.05$), and gray non-significant lipids.
- 985

986 **Figure 6: BCG-induced plasma lysophospholipids correlated with TLR- and mycobacterial** 987 **antigen-induced cytokine responses.**

- Peripheral blood was collected from early vs. delayed BCG immunized infants in Guinea Bissau 989 at 4 weeks of age and diluted for *in vitro* TLR agonist- and PPD-induced stimulation assay as 990 previously described (Jensen et al., 2015).
- 991 (A-F) Early administration of BCG was associated with perturbation of multiple LPCs as 992 compared to delayed BCG. LPC concentrations are depicted as boxplots. Significance 993 was calculated using the Mann-Whitney Rank Test between unpaired samples.
-
- 994 (G) Cytokines and chemokines were measured after multiple antigen recall responses of 995 delayed and early BCG newborn samples. Response from PMA, LPS (TLR4 agonist),
- 996 PAM3CSK4 (TLR 2/1 agonist), CLO75 (TLR 7/8), and PPD were correlated for 997 corresponding matched samples using Pearson correlations of all LPCs. Data are 998 presented as correlation estimates of cytokines/chemokines vs. LPCs. These estimates
- 999 were calculated from log_2 fold-changes for early BCG vs. delayed BCG.
- 1000 (H) The summary correlation coefficient (R) from selected significant cytokine and LPC 1001 correlations is depicted on a forest plot. The plot presented significant correlations with 1002 corresponding 95% CIs.

1003 **Figure 7: Concordance of significant metabolites across distinct human newborn cohorts** 1004 **demonstrates a common BCG-induced metabolic trajectory in early life.**

- 1005 (A)Untargeted global metabolomics profiling was conducted on peripheral blood of 1006 newborns vaccinated with EPI vaccines (BCG, HBV, and OPV) in The Gambia (n= 27) 1007 during the first week of life. Venn diagram summarizes the number of shared metabolite 1008 sets enriched after metabolite set enrichment analysis (MSEA, *MetaboAnalyst*) in The 1009 Gambia *in vivo* cohort (green), Boston *in vitro* cohort (yellow), and Guinea-Bissau *in* 1010 *vivo* 4-week blood collection (blue).
- 1011 (B) A number of significant metabolites per cohort based on their pattern level are illustrated. 1012 Data are presented as counts of significantly decreased or increased metabolites. BCG-1013 induced fold-changes were calculated as compared to control groups.
- 1014 (C) Significant metabolites shared by two or more cohorts were depicted as a heatmap with 1015 their log fold-change values comparing BCG-vaccinated vs. delayed (GB)/non-BCG 1016 vaccinated (Gambia) or BCG-stimulated vs. control for the Boston *in vitro* cohort. Paired 1017 samples were analyzed for Gambia and Boston samples, respectively. Direction of 1018 change is indicated by color code: blue, down; red, up; grey, not quantified.
- 1019 (D)Chord diagram of vaccine-induced metabolite associations revealed shared metabolite 1020 sets with vaccination compared to each control (Guinea-Bissau: blue, Boston: yellow, 1021 Gambia: green). Metabolite set bar widths are proportional to the number of associations 1022 across groups. Individual chords connected to each metabolite set indicate associations 1023 resulting from MSEA analysis.

1024 **Supplementary Figures:**

1025 **Figure S1. Flow chart of individuals with plasma samples analyzed in the study.**

- 1026 (A)Low birth weight newborns in Guinea Bissau were randomized to receive BCG at birth 1027 (early BCG) or delayed by 6 weeks (delayed BCG). In an immunological study nested 1028 within the trial, capillary blood samples were collected four weeks after randomization to 1029 assess the effect of BCG on *in vitro* antigen-induced recall cytokine responses. After the 1030 primary analyses (Jensen et al., 2015), remaining plasma samples of sufficient volume 1031 were utilized for subsequent metabolomic and lipidomic assays.
- 1032 (B) Human newborn cord blood samples (n= 12) were collected from healthy term newborns 1033 (≥ 37 weeks gestation) for *in vitro* stimulation with vehicle (saline) or BCG. The plasma samples were processed for metabolomics, complex lipid panel lipidomics, and multiplex 1035 cytokine/chemokine assays.
- 1036 (C) Newborns were recruited in The Gambia (West Africa). Each newborn provided a 1037 peripheral blood sample at the day of birth (DOL0) and subsets of newborns, each 1038 providing a second peripheral blood sample at either DOL1, 3, or 7. The newborns were 1039 assigned to either delayed-vaccinated up to 1 week (participant n= 13, total samples 1040 $n=26$) or EPI-vaccinated at birth (participant $n=14$, total samples $n=28$). Newborn 1041 peripheral venous blood was drawn directly into heparinized collection tubes and 1042 subjected to metabolomic assay.

1044 **Figure S2: Summary of quality control and assurance method for metabolomics Guinea-**1045 **Bissau (in vivo, upper panel) and Boston (in vitro, lower panel) datasets.**

- 1046 (A) and (F) Histogram of percent missing values for each metabolite
- 1047 (B) and (G) Histogram of percent missing values for each sample
- 1048 (C) and (H) Quality control and assurance metrics summary table
- 1049 (D) and (I) Pre-processing distribution before scaling and normalization
- 1050 (E) and (J) Post-processing distribution after scaling and normalization
- 1051

1043

1052 **Figure S3: Addition of BCG to human newborn cord blood** *in vitro* **perturbs the eicosanoid** 1053 **lipid pathway.**

- 1054 (A)Heparinized human cord blood was stimulated with saline control or BCG vaccine for 18 1055 hr after which the extracellular medium was collected and analyzed via complex lipid 1056 panel lipidomics. BCG alone was tested at high $(1:10 \text{ v/v})$ and low $(1:1000 \text{ v/v})$ 1057 concentrations as controls. For *in vitro* studies, the 1:1000 vol/vol ratio was used. A 1058 summary of the number of lipids quantified is illustrated. Data are presented as mean \pm 1059 SEM.
- 1060 (B)Comparison of lipid families showed that BCG-only controls (BCG vaccine alone) have 1061 lower measured lipids in most families than cord blood stimulated with vehicle or BCG. 1062 For *in vitro* treatments, BCG low (1:1000 vol/vol) concentration was used to stimulate 1063 cord blood. Lipid families with very low or undetectable concentrations after BCG-only 1064 low or BCG cord stimulation (1:1000 vol/vol) are depicted in red.
- 1065 (C) The Venn diagram of detected lipids illustrates that BCG-only controls had fewer lipids 1066 detected than *in vitro* control- or BCG-stimulated cord blood samples.
- 1067 (D-F) BCG-induced differentially abundant lipids (DALs) included fatty acid components
- 1068 such as prostaglandin E_2 (PGE₂) (panel D), docosahexaenoic acid (DHA 22:6) (panel E),
- 1069 linoleic acid (FFA 18:2) (panel G), and arachidonic acid (FFA 20:4) (panel H) suggesting

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2021.12.03.21267251;](https://doi.org/10.1101/2021.12.03.21267251) this version posted December 5, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted

1070 BCG modulates lipid mediators of inflammation (panel F). BCG induced a pro-inflammatory 1071 eicosanoid pathway pattern *in vitro*, decreasing anti-inflammatory DHA 22:6, FFA 18:2, and 1072 FFA 20:4 while increasing pro-inflammatory PGE2. Statistical analyses employed repeated 1073 measures t-test for participant samples. Data are presented with box and whiskers depicting 1074 quartiles and variability outside the quartiles.

1075

1076 **Figure S4: Early BCG group demonstrated enhanced cytokine production upon PPD re-**1077 **stimulation of heparinized blood collected 4 weeks post BCG vaccination.**

- 1078 (A-G) PPD-induced cytokines were compared in the early vs. delayed BCG groups. The 1079 early BCG group demonstrated significantly greater PPD-induced production of TNFα, IL5, 1080 IL6, IL17 and IFNγ. Groups were compared using the Wilcoxon Rank Sum Test. Data are
- 1081 depicted as geometric means. * *P* < 0.05: ** *P* < 0.01; *** *P* < 0.001 1082

1083 **Figure S5: BCG-induced cytokine and chemokine production in Boston human newborn** 1084 **cord blood** *in vitro***.**

- 1085 (A)Heatmap depicting changes in the production of 41 selected cytokines and chemokines 1086 after BCG *in vitro* stimulation for 18 hr. Two-sample t-tests with Benjamini, Krieger and 1087 Yekutieli correction comparing BCG-stimulated vs. vehicle control * *P* < 0.05: ** *P* < 1088 0.01; *** *P* < 0.001. Data are reported using Euclidean distance and Ward algorithm. 1089 (B-E) Selected inflammatory cytokines showed differences between vehicle control 1090 stimulated cord blood vs. BCG-stimulated cord blood. Paired student t-test used for data 1091 analysis * *P* < 0.05: ** *P* < 0.01; *** *P* < 0.001
- 1092

1093

1094

1095

1096

1097 **Table S1: Characteristics of newborn groups for Guinea-Bissau** *in vivo* **metabolomics** 1098 **profiling**

- 1099 Clinical data analyses for the study participants were assessed by metabolomics. Missing values
- 1100 were excluded. After the blood draw at 4 weeks after birth, the delayed group received catch-up
- 1101 BCG vaccination within 2 months of life. Normally distributed numerical values were tested
- 1102 with unpaired *t*-test with Welch's correction, presented as means with 95% confidence intervals
- 1103 (CI).
- 1104 *Significantly different (p<0.05).
- 1105 Abbreviations: BCG, Bacillus Calmette–Guérin; PPD, purified protein derivative; TST, Mantoux 1106 tuberculin skin test.
- 1107

1108 **Table S2: Significantly altered plasma metabolites in the early vs. delayed BCG group.** An

- 1109 unpaired t-test with Welch's correction was employed (nom. p<0.05) to identify altered
- 1110 metabolites in plasma samples derived from newborns receiving early vs. delayed BCG. Please
- 1111 see the spreadsheet.
- 1112

1113 **Table S3: BCG-Induced Metabolite Pathways enriched in newborn cohorts.** Metabolite Set

- 1114 Enrichment Analysis (MSEA) employed *MetaboAnalyst* to evaluate and group significant
- 1115 metabolites for each cohort, including Guinea-Bissau and Gambia *in vivo* and Boston *in vitro*.
- 1116 The table includes identified metabolite sets, the total number of metabolites corresponding to
- 1117 each set, expected metabolites, and the number of hits per cohort.
- 1118

1119 **Table S4: A birth dose of BCG induced plasma lipidome changes** *in vivo***.**

- 1120 Plasma from newborns in Guinea-Bissau whose blood was collected after 4 weeks for early vs.
- 1121 delayed BCG vaccination was subjected to lipidomics. Differentially abundant lipids (DALs)
- 1122 between treatment groups are reported along with their corresponding pathway, super-pathway,
- 1123 sub-pathway, lipid identification platforms, fold-change upon early BCG immunization (i.e., 1124 early BCG vs. delayed BCG), and significance.
- early BCG vs. delayed BCG), and significance.
- 1125

Table S5: BCG induced changes in plasma metabolites in newborn cord blood *in vitro***.
1127 Human newborn cord blood was stimulated** *in vitro* **for 18 hr with BCG (1:1000 vol:vol) or**

- 1127 Human newborn cord blood was stimulated *in vitro* for 18 hr with BCG (1:1000 vol:vol) or
- 1128 saline control prior to collecting the extracellular medium for metabolomics. Matrices were
- 1129 computed for indexed matched samples comparing BCG stimulation vs. saline vehicle control
- 1130 using the *WithinVariation* function in R package *mixOmics* v. 6.1.2. (See spreadsheet in the
- 1131 supplementary materials).
- 1132

1133 **Table S6: Tobit regression analysis of cytokine responses of** *ex vivo* **stimulated (PPD and**

1134 **control) whole blood samples from the Guinea-Bissau newborn cohort (pg/mL).**

- 1135 Cytokine measurements were performed on early BCG and delayed BCG newborn samples
- 1136 stimulated *in vitro* with RPMI control and PPD at 4 weeks as described (Jensen et al., 2015;
- 1137 Skogstrand et al., 2005). Results are reported as geometric mean ratios (GMR) and 95%
- 1138 confidence intervals (CI) with concentrations in pg/mL; n=119. Cytokines whose concentrations significantly differed between the early vs. delayed BCG group are indicated in bold.
- significantly differed between the early vs. delayed BCG group are indicated in bold.
- 1140 Abbreviations: BCG, Bacillus Calmette–Guérin; CI, confidence interval; PPD, purified protein
- 1141 derivative TB test; GMR, geometric mean range

1142 **Table S7: Addition of BCG to human cord blood** *in vitro* **induced plasma lipidome changes.**

- 1143 Human cord blood collected from a Boston cohort was stimulated *in vitro* for 18 hours with
- 1144 vehicle control vs. BCG. The extracellular medium (90% plasma vol/vol) was subsequently
- 1145 analyzed by lipidomics. Identified lipids were analyzed using a repeated-measures test for
- 1146 matched participants. Significant lipids were reported with their corresponding pathway, super-
- 1147 pathway, sub-pathway, platforms used, fold-change of treatment (matched BCG-stimulated vs.
- 1148 control), and significance level.
- 1149

1150 **Table S8 EPI-vaccination at birth alters the plasma metabolome.** Significant plasma

- 1151 metabolites in the EPI-vaccinated vs. delayed vaccinated (in the first week of life) newborns are
- 1152 shown. Peripheral blood was collected from a human newborn cohort in The Gambia (West
- 1153 Africa) that received EPI immunization (BCG, HBV, and OPV) either at birth (Day of Life
- 1154 (DOL)-0) or delayed immunization to DOL-7. Blood was promptly fractionated to generate
- 1155 cryopreserved plasma that was batch-analyzed for global metabolomics. Data were analyzed
- 1156 taking into account treatment groups (EPI-vaccinated at birth vs. delayed) and DOL.
- 1157

1158 **Table S9: Complex Lipid Panel lipidomics Guinea Bissau** *in vivo,* Assay coverage, individual 1159 lipid class species, and concentrations (μM) are reported.

1160

1161 **Table S10: Complex Lipid Panel lipidomics Boston** *in vitro.* Assay coverage, individual lipid 1162 class species, and concentrations (µM) are reported.

- 1163
- 1164

1165 **References**

- 1166 Ackerman, M.E., Barouch, D.H., and Alter, G. (2017). Systems serology for evaluation of HIV
- 1167 vaccine trials. Immunol Rev *275*, 262-270.
- 1168 Almeida, P.E., Silva, A.R., Maya-Monteiro, C.M., Töröcsik, D., D'Ávila, H., Dezsö, B., 1169 Magalhães, K.G., Castro-Faria-Neto, H.C., Nagy, L., and Bozza, P.T. (2009). Mycobacte
- Magalhães, K.G., Castro-Faria-Neto, H.C., Nagy, L., and Bozza, P.T. (2009). Mycobacterium
- 1170 bovis Bacillus Calmette-Guérin Infection Induces TLR2-Dependent Peroxisome Proliferator-
- 1171 Activated Receptor γ Expression and Activation: Functions in Inflammation, Lipid Metabolism, 1172 and Pathogenesis. The Journal of Immunology 183, 1337-1345.
- and Pathogenesis. The Journal of Immunology 183, 1337-1345.
- 1173 Amenyogbe, N., Levy, O., and Kollmann, T.R. (2015). Systems vaccinology: a promise for the
- 1174 young and the poor. Philos Trans R Soc Lond B Biol Sci *370*.
- Andersen, A., Fisker, A.B., Rodrigues, A., Martins, C., Ravn, H., Lund, N., Biering-Sorensen,
- 1176 S., Benn, C.S., and Aaby, P. (2018). National Immunization Campaigns with Oral Polio Vaccine
- 1177 Reduce All-Cause Mortality: A Natural Experiment within Seven Randomized Trials. Front 1178 Public Health *6*, 13.
- 1179 Angelidou, A., Conti, M.G., Diray-Arce, J., Benn, C.S., Shann, F., Netea, M.G., Liu, M., Potluri,
- 1180 L.P., Sanchez-Schmitz, G., Husson, R.*, et al.* (2020a). Licensed Bacille Calmette-Guerin (BCG)
- 1181 formulations differ markedly in bacterial viability, RNA content and innate immune activation.
- 1182 Vaccine *38*, 2229-2240.
- 1183 Angelidou, A., Diray-Arce, J., Conti, M.G., Netea, M.G., Blok, B.A., Liu, M., Sanchez-Schmitz,
- 1184 G., Ozonoff, A., van Haren, S.D., and Levy, O. (2021). Human Newborn Monocytes
- 1185 Demonstrate Distinct BCG-Induced Primary and Trained Innate Cytokine Production and
- 1186 Metabolic Activation In Vitro. Front Immunol *12*, 674334.
- 1187 Angelidou, A., Diray-Arce, J., Conti, M.G., Smolen, K.K., van Haren, S.D., Dowling, D.J.,
- 1188 Husson, R.N., and Levy, O. (2020b). BCG as a Case Study for Precision Vaccine Development:
- 1189 Lessons From Vaccine Heterogeneity, Trained Immunity, and Immune Ontogeny. Front 1190 Microbiol *11*, 332.
- 1191 Arts, R.J.W., Moorlag, S., Novakovic, B., Li, Y., Wang, S.Y., Oosting, M., Kumar, V., Xavier,
- 1192 R.J., Wijmenga, C., Joosten, L.A.B.*, et al.* (2018). BCG Vaccination Protects against
- 1193 Experimental Viral Infection in Humans through the Induction of Cytokines Associated with
- 1194 Trained Immunity. Cell Host Microbe *23*, 89-100 e105.
- 1195 Behar, S.M., Divangahi, M., and Remold, H.G. (2010). Evasion of innate immunity by
- 1196 Mycobacterium tuberculosis: is death an exit strategy? Nature Reviews Microbiology *8*, 668- 1197 674.
- 1198 Biering-Sorensen, S., Aaby, P., Lund, N., Monteiro, I., Jensen, K.J., Eriksen, H.B., Schaltz-
- 1199 Buchholzer, F., Jorgensen, A.S.P., Rodrigues, A., Fisker, A.B.*, et al.* (2017). Early BCG-
- 1200 Denmark and Neonatal Mortality Among Infants Weighing <2500 g: A Randomized Controlled
- 1201 Trial. Clin Infect Dis *65*, 1183-1190.
- 1202 Blok, B.A., de Bree, L.C.J., Diavatopoulos, D.A., Langereis, J.D., Joosten, L.A.B., Aaby, P., van
- 1203 Crevel, R., Benn, C.S., and Netea, M.G. (2020). Interacting, Nonspecific, Immunological Effects
- 1204 of Bacille Calmette-Guerin and Tetanus-diphtheria-pertussis Inactivated Polio Vaccinations: An
- 1205 Explorative, Randomized Trial. Clin Infect Dis *70*, 455-463.
- 1206 Boothby, M., and Rickert, R.C. (2017). Metabolic Regulation of the Immune Humoral Response.
- 1207 Immunity *46*, 743-755. Brook, B., Harbeson, D.J., Shannon, C.P., Cai, B., He, D., Ben-Othman, R., Francis, F., Huang,
- 1209 J., Varankovich, N., Liu, A.*, et al.* (2020). BCG vaccination-induced emergency granulopoiesis
- 1210 provides rapid protection from neonatal sepsis. Sci Transl Med *12*.

- 1211 Carneiro, A.B., Iaciura, B.M., Nohara, L.L., Lopes, C.D., Veas, E.M., Mariano, V.S., Bozza,
- 1212 P.T., Lopes, U.G., Atella, G.C., Almeida, I.C.*, et al.* (2013). Lysophosphatidylcholine triggers
- 1213 TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in
- 1214 peritoneal macrophages by inhibiting NF-kappaB translocation and MAPK/ERK
- 1215 phosphorylation. PLoS One *8*, e76233.
- 1216 Chen, M., Divangahi, M., Gan, H., Shin, D.S.J., Hong, S., Lee, D.M., Serhan, C.N., Behar, S.M.,
- 1217 and Remold, H.G. (2008). Lipid mediators in innate immunity against tuberculosis: opposing
- 1218 roles of PGE2 and LXA4 in the induction of macrophage death. Journal of Experimental
- 1219 Medicine *205*, 2791-2801.
- 1220 Chiurchiù, V., Leuti, A., and Maccarrone, M. (2018). Bioactive Lipids and Chronic
- 1221 Inflammation: Managing the Fire Within. Frontiers in Immunology *9*.
- 1222 Clipet-Jensen, C., Andersen, A., Jensen, A.K.G., Aaby, P., and Zaman, K. (2021). Out-of-
- 1223 Sequence Vaccinations With Measles Vaccine and Diphtheria-Tetanus-Pertussis Vaccine: A
- 1224 Reanalysis of Demographic Surveillance Data From Rural Bangladesh. Clin Infect Dis *72*, 1429- 1225 1436.
- 1226 Comstock, G.W. (1988). Identification of an effective vaccine against tuberculosis. Am Rev 1227 Respir Dis *138*, 479-480.
- 1228 Conti, M.G., Angelidou, A., Diray-Arce, J., Smolen, K.K., Lasky-Su, J., De Curtis, M., and
- 1229 Levy, O. (2020). Immunometabolic approaches to prevent, detect, and treat neonatal sepsis.
- 1230 Pediatr Res *87*, 399-405.
- 1231 Curtis, N., Sparrow, A., Ghebreyesus, T.A., and Netea, M.G. (2020). Considering BCG
- 1232 vaccination to reduce the impact of COVID-19. Lancet.
- 1233 Dela Pena-Ponce, M.G., Rodriguez-Nieves, J., Bernhardt, J., Tuck, R., Choudhary, N., Mengual,
- 1234 M., Mollan, K.R., Hudgens, M.G., Peter-Wohl, S., and De Paris, K. (2017). Increasing
- 1235 JAK/STAT Signaling Function of Infant CD4(+) T Cells during the First Year of Life. Front 1236 Pediatr *5*, 15.
- 1237 Diray-Arce, J., Conti, M.G., Petrova, B., Kanarek, N., Angelidou, A., and Levy, O. (2020).
- 1238 Integrative Metabolomics to Identify Molecular Signatures of Responses to Vaccines and 1239 Infections. Metabolites 10. 1239 Infections. Metabolites *10*.
- 1240 Diray-Arce, J., Miller, H.E.R., Henrich, E., Gerritsen, B., Mulè, M.P., Fourati, S., Gygi, J.,
- 1241 Hagan, T., Tomalin, L., Rychkov, D.*, et al.* (2021). The Immune Signatures Data Resource: A
- 1242 compendium of systems vaccinology datasets. bioRxiv, 2021.2011.2005.465336.
- 1243 Dowling, D.J., and Levy, O. (2014). Ontogeny of early life immunity. Trends Immunol *35*, 299- 1244 310.
- 1245 Evans, A.M., DeHaven, C.D., Barrett, T., Mitchell, M., and Milgram, E. (2009). Integrated,
- 1246 Nontargeted Ultrahigh Performance Liquid Chromatography/Electrospray Ionization Tandem
- 1247 Mass Spectrometry Platform for the Identification and Relative Quantification of the Small-
- 1248 Molecule Complement of Biological Systems. Analytical Chemistry *81*, 6656-6667.
- 1249 Fanos, V., Atzori, L., Makarenko, K., Melis, G.B., and Ferrazzi, E. (2013). Metabolomics
- 1250 application in maternal-fetal medicine. Biomed Res Int *2013*, 720514.
- 1251 Faustman, D.L. (2020). Benefits of BCG-induced metabolic switch from oxidative
- 1252 phosphorylation to aerobic glycolysis in autoimmune and nervous system diseases. J Intern Med.
- 1253 Fok, E.T., Davignon, L., Fanucchi, S., and Mhlanga, M.M. (2019). The lncRNA Connection 1254 Between Cellular Metabolism and Epigenetics in Trained Immunity. Frontiers in Immunolog
- 1254 Between Cellular Metabolism and Epigenetics in Trained Immunity. Frontiers in Immunology *9*.
- 1255 Freyne, B., Donath, S., Germano, S., Gardiner, K., Casalaz, D., Robins-Browne, R.M.,
- 1256 Amenyogbe, N., Messina, N.L., Netea, M.G., Flanagan, K.L.*, et al.* (2018). Neonatal BCG

- 1257 Vaccination Influences Cytokine Responses to Toll-like Receptor Ligands and Heterologous
- 1258 Antigens. J Infect Dis *217*, 1798-1808.
- 1259 Guijas, C., Montenegro-Burke, J.R., Warth, B., Spilker, M.E., and Siuzdak, G. (2018).
- 1260 Metabolomics activity screening for identifying metabolites that modulate phenotype. Nature 1261 Biotechnology *36*, 316-320.
- 1262 Haahr, S., Michelsen, S.W., Andersson, M., Bjorn-Mortensen, K., Soborg, B., Wohlfahrt, J.,
- 1263 Melbye, M., and Koch, A. (2016). Non-specific effects of BCG vaccination on morbidity among
- 1264 children in Greenland: a population-based cohort study. Int J Epidemiol *45*, 2122-2130.
- 1265 Hagan, T., Nakaya, H.I., Subramaniam, S., and Pulendran, B. (2015). Systems vaccinology:
- 1266 Enabling rational vaccine design with systems biological approaches. Vaccine *33*, 5294-5301.
- 1267 Higgins, J.P., Soares-Weiser, K., Lopez-Lopez, J.A., Kakourou, A., Chaplin, K., Christensen, H.,
- 1268 Martin, N.K., Sterne, J.A., and Reingold, A.L. (2016). Association of BCG, DTP, and measles 1269 containing vaccines with childhood mortality: systematic review. BMJ *355*, i5170.
- 1270 Jensen, K.J., Larsen, N., Biering-Sorensen, S., Andersen, A., Eriksen, H.B., Monteiro, I.,
- 1271 Hougaard, D., Aaby, P., Netea, M.G., Flanagan, K.L.*, et al.* (2015). Heterologous immunological
- 1272 effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: a randomized-
1273 controlled trial. J Infect Dis 211, 956-967.
- controlled trial. J Infect Dis 211, 956-967.
- 1274 Jia, P., Wang, Q., Chen, Q., Hutchinson, K.E., Pao, W., and Zhao, Z. (2014). MSEA: detection
- 1275 and quantification of mutation hotspots through mutation set enrichment analysis. Genome Biol 1276 *15*, 489.
- 1277 Johnson, C.H., Ivanisevic, J., and Siuzdak, G. (2016). Metabolomics: beyond biomarkers and
- 1278 towards mechanisms. Nature Reviews Molecular Cell Biology *17*, 451-459.
- 1279 Kan, B., Michalski, C., Fu, H., Au, H.H.T., Lee, K., Marchant, E.A., Cheng, M.F., Anderson-
- 1280 Baucum, E., Aharoni-Simon, M., Tilley, P.*, et al.* (2018). Cellular metabolism constrains innate 1281 immune responses in early human ontogeny. Nat Commun *9*, 4822.
- 1282 Kelly, B., and O'Neill, L.A. (2015). Metabolic reprogramming in macrophages and dendritic
- 1283 cells in innate immunity. Cell Res *25*, 771-784.
- 1284 Kjaergaard, J., Birk, N.M., Nissen, T.N., Thostesen, L.M., Pihl, G.T., Benn, C.S., Jeppesen,
- 1285 D.L., Pryds, O., Kofoed, P.E., Aaby, P.*, et al.* (2016). Nonspecific effect of BCG vaccination at
- 1286 birth on early childhood infections: a randomized, clinical multicenter trial. Pediatr Res *80*, 681- 1287 685.
- 1288 Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L.A., Ifrim, D.C., Saeed, S., Jacobs, C., van
- 1289 Loenhout, J., de Jong, D., Stunnenberg, H.G.*, et al.* (2012). Bacille Calmette-Guerin induces
- 1290 NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of
- 1291 monocytes. Proc Natl Acad Sci U S A *109*, 17537-17542.
- 1292 Knuplez, E., and Marsche, G. (2020). An Updated Review of Pro- and Anti-Inflammatory
- 1293 Properties of Plasma Lysophosphatidylcholines in the Vascular System. Int J Mol Sci *21*.
- 1294 Kollmann, T.R. (2013). Variation between Populations in the Innate Immune Response to
- 1295 Vaccine Adjuvants. Front Immunol *4*, 81.
- 1296 Langley, R.J., Tsalik, E.L., van Velkinburgh, J.C., Glickman, S.W., Rice, B.J., Wang, C., Chen,
- 1297 B., Carin, L., Suarez, A., Mohney, R.P.*, et al.* (2013). An integrated clinico-metabolomic model
- 1298 improves prediction of death in sepsis. Sci Transl Med *5*, 195ra195.
- 1299 Law, S.H., Chan, M.L., Marathe, G.K., Parveen, F., Chen, C.H., and Ke, L.Y. (2019). An 1300 Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases. Int J Mol S
- 1300 Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases. Int J Mol Sci *20*.

- 1301 Lawton, K.A., Berger, A., Mitchell, M., Milgram, K.E., Evans, A.M., Guo, L., Hanson, R.W.,
- 1302 Kalhan, S.C., Ryals, J.A., and Milburn, M.V. (2008). Analysis of the adult human plasma 1303 metabolome. Pharmacogenomics *9*, 383-397.
- 1304 Lee, A.H., Shannon, C.P., Amenyogbe, N., Bennike, T.B., Diray-Arce, J., Idoko, O.T., Gill,
- 1305 E.E., Ben-Othman, R., Pomat, W.S., van Haren, S.D.*, et al.* (2019). Dynamic molecular changes
- 1306 during the first week of human life follow a robust developmental trajectory. Nat Commun *10*, 1307 1092.
- 1308 Lee, H.-J., Ko, H.-J., Song, D.-K., and Jung, Y.-J. (2018). Lysophosphatidylcholine Promotes
- 1309 Phagosome Maturation and Regulates Inflammatory Mediator Production Through the Protein
-
- 1310 Kinase A–Phosphatidylinositol $3\Box$ Kinase–p38 Mitogen-Activated Protein Kinase Signaling 1311 Pathway During Mycobacterium tuberculosis Infection in Mouse Macrophages. Frontiers in Pathway During Mycobacterium tuberculosis Infection in Mouse Macrophages. Frontiers in
- 1312 Immunology *9*.
- 1313 Li, S., Sullivan, N.L., Rouphael, N., Yu, T., Banton, S., Maddur, M.S., McCausland, M., Chiu,
- 1314 C., Canniff, J., Dubey, S.*, et al.* (2017). Metabolic Phenotypes of Response to Vaccination in
- 1315 Humans. Cell *169*, 862-877 e817.
- 1316 Li, Z., Xie, Y., Xiao, Q., and Wang, L. (2020). Terminal osseous dysplasia with pigmentary
- 1317 defects in a Chinese girl with the FLNA mutation: A case report and published work review. J
- 1318 Dermatol *47*, 295-299.
- 1319 Libraty, D.H., Zhang, L., Woda, M., Acosta, L.P., Obcena, A., Brion, J.D., and Capeding, R.Z.
- 1320 (2014). Neonatal BCG vaccination is associated with enhanced T-helper 1 immune responses to 1321 heterologous infant vaccines. Trials Vaccinol *3*, 1-5.
- 1322 Lochner, M., Berod, L., and Sparwasser, T. (2015). Fatty acid metabolism in the regulation of T 1323 cell function. Trends Immunol *36*, 81-91.
- 1324 Lofgren, L., Stahlman, M., Forsberg, G.B., Saarinen, S., Nilsson, R., and Hansson, G.I. (2012).
- 1325 The BUME method: a novel automated chloroform-free 96-well total lipid extraction method for 1326 blood plasma. J Lipid Res *53*, 1690-1700.
- 1327 Long, T., Hicks, M., Yu, H.C., Biggs, W.H., Kirkness, E.F., Menni, C., Zierer, J., Small, K.S.,
- 1328 Mangino, M., Messier, H.*, et al.* (2017). Whole-genome sequencing identifies common-to-rare 1329 variants associated with human blood metabolites. Nat Genet *49*, 568-578.
- 1330 Lund, N., Andersen, A., Hansen, A.S., Jepsen, F.S., Barbosa, A., Biering-Sorensen, S.,
- 1331 Rodrigues, A., Ravn, H., Aaby, P., and Benn, C.S. (2015). The Effect of Oral Polio Vaccine at
- 1332 Birth on Infant Mortality: A Randomized Trial. Clin Infect Dis *61*, 1504-1511.
- 1333 Marchant, A., Goetghebuer, T., Ota, M.O., Wolfe, I., Ceesay, S.J., De Groote, D., Corrah, T.,
- 1334 Bennett, S., Wheeler, J., Huygen, K.*, et al.* (1999). Newborns develop a Th1-type immune
- 1335 response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J Immunol *163*, 2249- 1336 2255.
- 1337 McFarland, C.T., Fan, Y.Y., Chapkin, R.S., Weeks, B.R., and McMurray, D.N. (2008). Dietary
- 1338 polyunsaturated fatty acids modulate resistance to Mycobacterium tuberculosis in guinea pigs. J 1339 Nutr *138*, 2123-2128.
- 1340 Members, M.S.I.B., Sansone, S.A., Fan, T., Goodacre, R., Griffin, J.L., Hardy, N.W., Kaddurah-
- 1341 Daouk, R., Kristal, B.S., Lindon, J., Mendes, P.*, et al.* (2007). The metabolomics standards
- 1342 initiative. Nat Biotechnol *25*, 846-848.
- 1343 Moorlag, S., Arts, R.J.W., van Crevel, R., and Netea, M.G. (2019). Non-specific effects of BCG
1344 vaccine on viral infections. Clin Microbiol Infect 25, 1473-1478.
- 1344 vaccine on viral infections. Clin Microbiol Infect *25*, 1473-1478.
- 1345 Moorlag, S., van Deuren, R.C., van Werkhoven, C.H., Jaeger, M., Debisarun, P., Taks, E.,
- 1346 Mourits, V.P., Koeken, V., de Bree, L.C.J., Ten Doesschate, T.*, et al.* (2020). Safety and

- 1347 COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort
- 1348 Study. Cell Rep Med *1*, 100073.
- 1349 Mussap, M., Antonucci, R., Noto, A., and Fanos, V. (2013). The role of metabolomics in
- 1350 neonatal and pediatric laboratory medicine. Clin Chim Acta *426*, 127-138.
- 1351 Nakaya, H.I., Clutterbuck, E., Kazmin, D., Wang, L., Cortese, M., Bosinger, S.E., Patel, N.B.,
- 1352 Zak, D.E., Aderem, A., Dong, T.*, et al.* (2016). Systems biology of immunity to MF59-
- 1353 adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proc
- 1354 Natl Acad Sci U S A *113*, 1853-1858.
- 1355 Nakaya, H.I., Wrammert, J., Lee, E.K., Racioppi, L., Marie-Kunze, S., Haining, W.N., Means,
- 1356 A.R., Kasturi, S.P., Khan, N., Li, G.M.*, et al.* (2011). Systems biology of vaccination for 1357 seasonal influenza in humans. Nat Immunol *12*, 786-795.
- 1358 Netea, M.G., Joosten, L.A., Latz, E., Mills, K.H., Natoli, G., Stunnenberg, H.G., O'Neill, L.A.,
- 1359 and Xavier, R.J. (2016). Trained immunity: A program of innate immune memory in health and 1360 disease. Science *352*, aaf1098.
- 1361 O'Neill, L.A., Kishton, R.J., and Rathmell, J. (2016). A guide to immunometabolism for
- 1362 immunologists. Nat Rev Immunol *16*, 553-565.
- 1363 Ojala, P.J., Hirvonen, T.E., Hermansson, M., Somerharju, P., and Parkkinen, J. (2007). Acyl
- 1364 chain-dependent effect of lysophosphatidylcholine on human neutrophils. J Leukoc Biol *82*, 1365 1501-1509.
- 1366 Okita, M., Gaudette, D.C., Mills, G.B., and Holub, B.J. (1997). Elevated levels and altered fatty
- 1367 acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. Int J 1368 Cancer *71*, 31-34.
- 1369 Perrin-Cocon, L., Agaugue, S., Coutant, F., Saint-Mezard, P., Guironnet-Paquet, A., Nicolas,
- 1370 J.F., Andre, P., and Lotteau, V. (2006). Lysophosphatidylcholine is a natural adjuvant that
- 1371 initiates cellular immune responses. Vaccine *24*, 1254-1263.
- 1372 Petrick, L.M., Schiffman, C., Edmands, W.M.B., Yano, Y., Perttula, K., Whitehead, T., Metayer,
- 1373 C., Wheelock, C.E., Arora, M., Grigoryan, H.*, et al.* (2019). Metabolomics of neonatal blood
- 1374 spots reveal distinct phenotypes of pediatric acute lymphoblastic leukemia and potential effects 1375 of early-life nutrition. Cancer Lett *452*, 71-78.
- 1376 Pettengill, M.A., van Haren, S.D., and Levy, O. (2014). Soluble mediators regulating immunity 1377 in early life. Front Immunol *5*, 457.
- 1378 Playdon, M.C., Ziegler, R.G., Sampson, J.N., Stolzenberg-Solomon, R., Thompson, H.J., Irwin,
- 1379 M.L., Mayne, S.T., Hoover, R.N., and Moore, S.C. (2017). Nutritional metabolomics and breast 1380 cancer risk in a prospective study. Am J Clin Nutr *106*, 637-649.
- 1381 Prentice, S., Nassanga, B., Webb, E.L., Akello, F., Kiwudhu, F., Akurut, H., Elliott, A.M., Arts,
- 1382 R.J.W., Netea, M.G., Dockrell, H.M.*, et al.* (2021). BCG-induced non-specific effects on
- 1383 heterologous infectious disease in Ugandan neonates: an investigator-blind randomised
- 1384 controlled trial. Lancet Infect Dis *21*, 993-1003.
- 1385 Reinke, S.N., Walsh, B.H., Boylan, G.B., Sykes, B.D., Kenny, L.C., Murray, D.M., and
- 1386 Broadhurst, D.I. (2013). 1H NMR derived metabolomic profile of neonatal asphyxia in umbilical
- 1387 cord serum: implications for hypoxic ischemic encephalopathy. J Proteome Res *12*, 4230-4239.
- 1388 Rothman, K.J. (1990). No Adjustments Are Needed for Multiple Comparisons. Epidemiology *1*,
- 1389 43-46.
1390 Sanche
- Sanchez-Schmitz, G., and Levy, O. (2011). Development of newborn and infant vaccines. Sci
- 1391 Transl Med *3*, 90ps27.

- 1392 Sanchez-Schmitz, G., Stevens, C.R., Bettencourt, I.A., Flynn, P.J., Schmitz-Abe, K., Metser, G.,
- 1393 Hamm, D., Jensen, K.J., Benn, C., and Levy, O. (2018). Microphysiologic Human Tissue
- 1394 Constructs Reproduce Autologous Age-Specific BCG and HBV Primary Immunization in vitro. 1395 Front Immunol *9*, 2634.
- 1396 Scheid, A., Borriello, F., Pietrasanta, C., Christou, H., Diray-Arce, J., Pettengill, M.A., Joshi, S.,
- 1397 Li, N., Bergelson, I., Kollmann, T.*, et al.* (2018). Adjuvant Effect of Bacille Calmette-Guerin on
- 1398 Hepatitis B Vaccine Immunogenicity in the Preterm and Term Newborn. Front Immunol *9*, 29.
- 1399 Sharma, N., Akhade, A.S., Ismaeel, S., and Qadri, A. (2020). Serum-borne lipids amplify TLR-1400 activated inflammatory responses. J Leukoc Biol.
- 1401 Skogstrand, K., Thorsen, P., Norgaard-Pedersen, B., Schendel, D.E., Sorensen, L.C., and
- 1402 Hougaard, D.M. (2005). Simultaneous measurement of 25 inflammatory markers and
- 1403 neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clin Chem 1404 *51*, 1854-1866.
- 1405 Soehnlein, O., Lindbom, L., and Weber, C. (2009). Mechanisms underlying neutrophil-mediated 1406 monocyte recruitment. Blood *114*, 4613-4623.
- 1407 Sorup, S., Benn, C.S., Poulsen, A., Krause, T.G., Aaby, P., and Ravn, H. (2016). Simultaneous
- 1408 vaccination with MMR and DTaP-IPV-Hib and rate of hospital admissions with any infections:
- 1409 A nationwide register based cohort study. Vaccine *34*, 6172-6180.
- 1410 Spicer, R.A., Salek, R., and Steinbeck, C. (2017). A decade after the metabolomics standards
- 1411 initiative it's time for a revision. Sci Data *4*, 170138.
- 1412 Stenken, J.A., and Poschenrieder, A.J. (2015). Bioanalytical chemistry of cytokines--a review. 1413 Anal Chim Acta *853*, 95-115.
- 1414 Sumner, L.W., Amberg, A., Barrett, D., Beale, M.H., Beger, R., Daykin, C.A., Fan, T.W., Fiehn,
- 1415 O., Goodacre, R., Griffin, J.L.*, et al.* (2007). Proposed minimum reporting standards for
- 1416 chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards
- 1417 Initiative (MSI). Metabolomics *3*, 211-221.
- 1418 Thysen, S.M., Rodrigues, A., Aaby, P., and Fisker, A.B. (2019). Out-of-sequence DTP and
- 1419 measles vaccinations and child mortality in Guinea-Bissau: a reanalysis. BMJ Open *9*, e024893.
- 1420 Uhl, O., Fleddermann, M., Hellmuth, C., Demmelmair, H., and Koletzko, B. (2016).
- 1421 Phospholipid Species in Newborn and 4 Month Old Infants after Consumption of Different
- 1422 Formulas or Breast Milk. PloS one *11*, e0162040.
- 1423 Welaga, P., Oduro, A., Debpuur, C., Aaby, P., Ravn, H., Andersen, A., Binka, F., and Hodgson,
- 1424 A. (2017). Fewer out-of-sequence vaccinations and reduction of child mortality in Northern 1425 Ghana. Vaccine *35*, 2496-2503.
- 1426 White, O.J., McKenna, K.L., Bosco, A., A, H.J.v.d.B., Richmond, P., and Holt, P.G. (2012). A
- 1427 genomics-based approach to assessment of vaccine safety and immunogenicity in children.
- 1428 Vaccine *30*, 1865-1874.
- 1429 Whittaker, E., Goldblatt, D., McIntyre, P., and Levy, O. (2018). Neonatal Immunization:
- 1430 Rationale, Current State, and Future Prospects. Front Immunol *9*, 532.
- 1431 World Health, O. (2020). Children: Improving Survival and Well-being.
- 1432 Xia, J., Sinelnikov, I.V., Han, B., and Wishart, D.S. (2015). MetaboAnalyst 3.0--making
- 1433 metabolomics more meaningful. Nucleic Acids Res *43*, W251-257.
- 1434 Xia, J., and Wishart, D.S. (2011). Metabolomic data processing, analysis, and interpretation
1435 using MetaboAnalyst. Curr Protoc Bioinformatics Chapter 14, Unit 14 10.
- 1435 using MetaboAnalyst. Curr Protoc Bioinformatics *Chapter 14*, Unit 14 10.
- 1436 Xia, J., and Wishart, D.S. (2016). Using MetaboAnalyst 3.0 for Comprehensive Metabolomics
- 1437 Data Analysis. Curr Protoc Bioinformatics *55*, 14 10 11-14 10 91.

- 1438 Yan, J.-J., Jung, J.-S., Lee, J.-E., Lee, J., Huh, S.-O., Kim, H.-S., Jung, K.C., Cho, J.-Y., Nam, J.-
- 1439 S., Suh, H.-W.*, et al.* (2004). Therapeutic effects of lysophosphatidylcholine in experimental 1440 sepsis. Nature Medicine *10*, 161-167.
-
- 1441 Zimmermann, P., Donath, S., Perrett, K.P., Messina, N.L., Ritz, N., Netea, M.G., Flanagan, K.L.,
- 1442 van der Klis, F.R.M., Curtis, N., and group, M.B. (2019). The influence of neonatal Bacille
- 1443 Calmette-Guerin (BCG) immunisation on heterologous vaccine responses in infants. Vaccine *37*, 1444 3735-3744.
- 1445
- 1446

In Wivo Assay: Guinea-Bissau Cohortino has granted med Rxiv a license to the **COLOGIC CONCORDITY** to has granted med Rxiv a license to the this made available under a CC-BY-NC-ND 4.0 International license. **A** medRxiv preprint doi: [https://doi.org/10.1101/2021.12.03.21267251;](https://doi.org/10.1101/2021.12.03.21267251) this version posted December 5, 2021. The copyright holder for this preprint
↑ VIVO VASSIONTIfics thi Pretorial is the IU model in the granted medRxiv a l

In Vitro **Assay: Boston Cohort B**

Validation Cohort: EPIC-001 Gambia pilot cohort C

significant lipids

